|
Old Dog, New Tricks: Oxybutynin for the Treatment of Androgen Deprivation Therapy–Related
Vasomotor Symptoms
Mar 26, 2026 Alliance A222001: Oxybutynin Versus Placebo for the Treatment of Hot Flashes in Patients Receiving Androgen-Deprivation Therapy for Prostate Cancer Mar 26, 2026 Ending the Controversy Around Pretreatment Dihydropyrimidine Dehydrogenase (DPD/DPYD) Testing Heightens the Controversy Over Appropriate Fluoropyrimidine Dosing Mar 26, 2026 Dear Doctor: We Still Have No Idea of What Dose of Capecitabine You Should Prescribe Mar 26, 2026 Final Efficacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With Advanced RET Fusion–Positive Non–Small Cell Lung Cancer Mar 26, 2026 Alliance A222001: Oxybutynin Versus Placebo for the Treatment of Hot Flashes in Patients Receiving Androgen-Deprivation Therapy for Prostate Cancer Mar 26, 2026 Old Dog, New Tricks: Oxybutynin for the Treatment of Androgen Deprivation Therapy–Related Vasomotor Symptoms Mar 26, 2026 Fullerene for Reducing Acute Radiation Dermatitis in Patients Undergoing Radiotherapy for Head and Neck Cancer: A Phase II, Double-Blind, Randomized Controlled Trial Mar 26, 2026 Results From the Genetic Information and Family Testing Study: A Cluster-Randomized Trial Mar 26, 2026 Trastuzumab Rezetecan in Human Epidermal Growth Factor Receptor 2–Expressing Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer: A Multicenter, Open-Label, Phase I Trial Mar 26, 2026 Residual Absolute Volume of Blastema as a Predictor of Clinical Outcomes in Patients With Wilms Tumor: A Report From the SIOP WT 2001 Study Mar 26, 2026 Trial Design and Objectives for Patients With Prostate Cancer: Recommendations From the Prostate Cancer Working Group 4 Mar 26, 2026 Blood-Brain Barrier Heterogeneity in NRG BN007: Implications for Immunotherapy Delivery Mar 26, 2026 Reply to: Blood-Brain Barrier Heterogeneity in NRG BN007: Implications for Immunotherapy Delivery Mar 26, 2026 Reply to: Blood-Brain Barrier Heterogeneity in NRG BN007: Implications for Immunotherapy Delivery Mar 26, 2026 Blood-Brain Barrier Heterogeneity in NRG BN007: Implications for Immunotherapy Delivery Mar 26, 2026 From Thresholds to Tumor Sidedness: Reframing Human Epidermal Growth Factor Receptor 2 in Colorectal Cancer Mar 26, 2026 Reply to: From Thresholds to Tumor Sidedness: Reframing Human Epidermal Growth Factor Receptor 2 in Colorectal Cancer Mar 26, 2026 Reply to: From Thresholds to Tumor Sidedness: Reframing Human Epidermal Growth Factor Receptor 2 in Colorectal Cancer Mar 26, 2026 From Thresholds to Tumor Sidedness: Reframing Human Epidermal Growth Factor Receptor 2 in Colorectal Cancer Mar 26, 2026 |
Medicaid Expansion and Stage at Diagnosis, Timely Initiation and Receipt of Guideline-Concordant Treatment, and Survival Among People With Non–Small Cell Lung Cancer Journal of Clinical Oncology, Volume 44, Issue 14, Page 1296-1308, May 2026. <br/> 2026-05-10T07:00:00Z First-in-Human Study of IL15–Activated Cytokine-Induced Killer Cells After Allogeneic HCT Shows Durable Remission and Serotherapy-Associated Immune Reconstitution in Leukemia Journal of Clinical Oncology, Volume 44, Issue 14, Page 1323-1336, May 2026. <br/> 2026-05-10T07:00:00Z Phase I Study of Mosperafenib, a Novel Paradox Breaker B-Raf Proto-Oncogene Serine/Threonine Kinase (BRAF) Inhibitor, in Patients With BRAF V600–Mutant Solid Tumors Journal of Clinical Oncology, Volume 44, Issue 14, Page 1337-1348, May 2026. <br/> 2026-05-10T07:00:00Z Systemic Treatment of Thyroid Cancer: ASCO Guideline Journal of Clinical Oncology, Volume 44, Issue 14, Page 1349-1372, May 2026. <br/> 2026-05-10T07:00:00Z Radiographic Progression With and Without Prostate-Specific Antigen Rise in Patients With Advanced Prostate Cancer Treated With Enzalutamide Journal of Clinical Oncology, Volume 44, Issue 14, Page 1309-1322, May 2026. <br/> 2026-05-10T07:00:00Z The Pathologic Response Evaluation and Detection in Circulating Tumor-DNA Study: Ultrasensitive Circulating Tumor-DNA Assessment of Breast Cancer Minimal Residual Disease Journal of Clinical Oncology, Volume 44, Issue 14, Page 1283-1295, May 2026. <br/> 2026-05-10T07:00:00Z Is Unmutated IgG1 a Wrong Choice for Therapeutic Antibodies Targeting Immune Checkpoints? Lessons From the Clinical Failures of the First Anti–TIGIT Antibodies Journal of Clinical Oncology, Volume 44, Issue 14, Page 1280-1282, May 2026. <br/> 2026-05-10T07:00:00Z Methodologic Considerations for Subsequent Colorectal Cancer in Survivors of Childhood Cancer Journal of Clinical Oncology, Volume 44, Issue 14, Page 1375-1376, May 2026. <br/> 2026-05-10T07:00:00Z Beyond Parametric Assumptions: Unsupervised Methods Enhance DNA Repair Gene Discovery in SMARCAL1 Identification Journal of Clinical Oncology, Volume 44, Issue 14, Page 1373-1374, May 2026. <br/> 2026-05-10T07:00:00Z Erratum: Phase I Trial of GD2.CART Cells Augmented With Constitutive Interleukin-7 Receptor for Treatment of High-Grade Pediatric CNS Tumors Journal of Clinical Oncology, Volume 44, Issue 14, Page 1379-1379, May 2026. <br/> 2026-05-10T07:00:00Z Erratum: Tissue-Free Circulating Tumor DNA Assay and Patient Outcome in a Phase III Trial of FOLFOX-Based Adjuvant Chemotherapy (Alliance N0147) Journal of Clinical Oncology, Volume 44, Issue 14, Page 1379-1379, May 2026. <br/> 2026-05-10T07:00:00Z Reply to: Methodologic Considerations for Subsequent Colorectal Cancer in Survivors of Childhood Cancer Journal of Clinical Oncology, Volume 44, Issue 14, Page 1376-1378, May 2026. <br/> 2026-05-10T07:00:00Z Reply to: Beyond Parametric Assumptions: Unsupervised Methods Enhance DNA Repair Gene Discovery in SMARCAL1 Identification Journal of Clinical Oncology, Volume 44, Issue 14, Page 1374-1375, May 2026. <br/> 2026-05-10T07:00:00Z From Prognosis to Action: Circulating Tumor DNA and the Next Phase of Risk Stratification in Triple-Negative Breast Cancer Journal of Clinical Oncology, Volume 44, Issue 14, Page 1273-1276, May 2026. <br/> 2026-05-10T07:00:00Z Evolving Medicaid Policy and Implications for High-Quality Cancer Care Journal of Clinical Oncology, Volume 44, Issue 14, Page 1277-1279, May 2026. <br/> 2026-05-10T07:00:00Z The Liver We Share Journal of Clinical Oncology, Ahead of Print. <br/> |
Base Editing of HBG1 and HBG2 Promoters for Sickle Cell Disease
In this study involving persons with sickle cell disease, adenine base editing was used to target the promoters of HBG1 and HBG2 in autologous hematopoietic stem cells to increase fetal hemoglobin expression. 2026-05-07
Daraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cancer In a phase 1–2 study of daraxonrasib, treatment-related adverse events of grade 3 or higher occurred in 30% of patients with previously treated RAS-mutated pancreatic cancer, and up to 35% of patients had an objective response. 2026-05-07
Reforming Payment for Clinician-Administered Drugs — Most-Favored-Nation Pricing in Medicare Part B The administration recently announced a new payment model to align some Medicare Part B drug payments with international pricing benchmarks. Various factors could affect the model’s scope and impact. 2026-05-07
Science behind the Study: Advances in RAS Therapeutics for Pancreatic Cancer The authors describe the scientific foundations of a phase 1–2 study of daraxonrasib to treat metastatic pancreatic ductal adenocarcinomas. 2026-05-07
Reducing Bacterial Contamination of Blood Bags with a Double Knot In a study involving 180 blood bags, use of a double-knot closure rather than the usual single knot prevented bacterial contamination. This strategy may reduce the risk of blood-product contamination in resource-limited settings. 2026-05-07
Mim8 Bispecific Antibody Prophylaxis in Hemophilia A with or without Inhibitors Among patients with hemophilia A, the annualized rate of treated bleeding events with Mim8 was more than 96% lower than with on-demand therapy and more than 42% lower than with clotting factor prophylaxis. 2026-04-30
First-Line Zongertinib in Advanced HER2-Mutant Non–Small-Cell Lung Cancer In a phase 1 trial of first-line zongertinib for HER2-mutated non–small-cell lung cancer, an objective response occurred in 76% of patients, with a median progression-free survival of 14.4 months. 2026-04-30
Barrett’s Esophagus This article summarizes the pathogenesis, diagnosis, and management of Barrett’s esophagus, a reflux-related condition with increased adenocarcinoma risk, highlighting endoscopic diagnosis, surveillance, and early curative therapy. 2026-04-30
Science behind the Study: A Second Factor VIIIa Mimetic for Hemophilia A The author describes the scientific foundations and implications of the results of a randomized, controlled trial of Mim8, a new mimetic of factor VIIIa, to treat hemophilia A. 2026-04-30
Membranoproliferative Glomerulonephritis Due to Cryoglobulinemia A 60-year-old woman with follicular lymphoma was evaluated for swelling and proteinuria that had persisted for 2 weeks. The patient’s plasma was clear at 37°C but turbid at 4°C. A kidney biopsy was performed. 2026-04-30
EGFR’s Poor Sibling The discovery that many lung cancers are driven by a single dominant constitutively activated “driver” oncogene represented a quantum leap in the therapy of lung cancer. Potent small molecules were developed that could turn off these genes, with dramatic clinical therapeutic efficacy. Before their discovery, cancer therapeutics were identified by... 2026-04-30
CD19 CAR T-Cell Therapy for Treatment of Chronic Graft-versus-Host Disease In a patient with relapsed B-cell acute lymphoblastic leukemia and chronic GVHD, CD19 CAR T-cell therapy led to leukemia remission for 1 year and sustained resolution of active chronic GVHD without other immunosuppressive therapy. 2026-04-30
Transdermal Estradiol Patches in Locally Advanced Prostate Cancer Among men with locally advanced prostate cancer, transdermal estradiol was noninferior to LHRH agonists for 3-year metastasis-free survival and led to a lower incidence of hot flashes but a higher incidence of gynecomastia. 2026-04-23
Asundexian for Secondary Stroke Prevention In a placebo-controlled trial involving patients with noncardioembolic ischemic stroke or high-risk TIA, asundexian added to antiplatelet therapy led to a lower risk of ischemic stroke without increasing major bleeding. 2026-04-16
Ianalumab plus Eltrombopag in Immune Thrombocytopenia In a phase 3 trial, ianalumab plus eltrombopag led to a longer time to treatment failure than placebo plus eltrombopag, with a stable platelet response at 6 months in a higher percentage of patients with 9 mg/kg of ianalumab than with placebo. 2026-04-16
Sex Hormone Influences on Venous Thrombotic and Cardiovascular Risk Combined oral contraceptives and hormone-replacement therapy increase the risk of venous thromboembolism, although the absolute risk is low. Transdermal estradiol and micronized progesterone carry lower risk. 2026-04-16
Asundexian for Noncardioembolic Ischemic Stroke Despite the implementation of efficacious interventions for secondary prevention, patients with ischemic stroke or transient ischemic attack (TIA) remain at substantial residual risk for short- and long-term recurrent ischemic stroke and coronary events.1,2 Approximately three quarters of ischemic strokes or TIAs are noncardioembolic and may be attributable to... 2026-04-16
The Dismantling of Environmental Protections — A Grave Threat to America’s Health The Trump administration’s wide-ranging actions to dismantle U.S. environmental regulations will cause long-lasting health harms, disproportionately affecting low-income and other vulnerable groups. 2026-04-16
Hepatic Pseudoprogression after Treatment with Nectin-4–Targeted Antibody–Drug Conjugate In a patient with metastatic cervical cancer treated with the nectin-4–targeted antibody–drug conjugate bulumtatug fuvedotin, a new hepatic lesion proved to be pseudoprogression and resolved with continued therapy. 2026-04-16
Stenting for Post-Thrombotic Syndrome — A Step Forward Post-thrombotic syndrome is the most common chronic complication of deep-vein thrombosis (DVT), affecting 20 to 50% of patients with DVT and causing debilitating symptoms involving the limbs — including pain, swelling, skin changes, and venous ulcers — that substantially reduce quality of life and impose considerable socioeconomic burden.1 ... 2026-04-13
|
|
|
| |||
|
[Editorial] War in the Middle East: collateral damage
A month after the USA and Israel launched attacks on Iran, Iran and the USA agreed to a conditional 2-week ceasefire on April 8, 2026. However, strikes continued in Lebanon, and after peace talks failed to come to a resolution an end to the war is no closer at the time of writing and the situation in the region remains precarious. Furthermore, the effects of the US–Israel–Iran war are being felt not only in the region, but also globally, and the impact on health care worldwide is under-appreciated and likely long-lasting. Fri, 01 May 2026 00:00:00 -0700
[Comment] AKT-targeted triplet therapy in advanced breast cancer The advent of CDK4/6 inhibitors combined with endocrine therapy has substantially transformed the treatment approach for patients with HR+/HER2– metastatic breast cancer;1 however, acquired resistance inevitably develops, making the optimal sequencing of subsequent targeted therapies a substantial challenge. Aberrant activation of the PI3K/AKT/PTEN signalling axis is frequently identified as a key contributor to CDK4/6 inhibitor cross-resistance, providing a robust biological rationale for therapeutic intervention. Fri, 01 May 2026 00:00:00 -0700
[Comment] Beyond efficacy: CDK4/6 inhibitors in metastatic breast cancer Over the past decade, phase 3 trials have consistently demonstrated substantial progression-free survival and overall survival improvements with the addition of CDK4/6 inhibitors to endocrine therapy. The meta-analysis of Beshr and colleagues1 in The Lancet Oncology provides the most up-to-date analysis of data from phase 3 trials comparing CDK4/6 inhibitors plus endocrine therapy with endocrine therapy alone. By consolidating survival results, efficacy of this drug class in treatment of HR+/HER2– metastatic breast cancer is reaffirmed. Fri, 01 May 2026 00:00:00 -0700
[Comment] An old tool for new strategies in advanced prostate cancer Prostate-specific antigen (PSA) was discovered in 1960 and introduced as a biomarker for prostate cancer in 1987.1 Since then, PSA has been used for screening, detecting recurrence after prostatectomy or radiotherapy, and monitoring treatment response. Early work also demonstrated that PSA concentrations measured 6–9 months after initiating castration represent a major prognostic factor in metastatic castration-sensitive prostate cancer.2 Fri, 01 May 2026 00:00:00 -0700
[Comment] Refined outcome prediction in patients with extremity soft tissue sarcoma The rarity and heterogenous presentation of extremity soft tissue sarcomas complicates large-scale studies on diagnosis, disease monitoring, and outcome prediction. Histological subtype, grading, tumour size, location, resectability (with wide margins), administration of adjuvant or neoadjuvant radiotherapy, and chemotherapy all influence oncological outcomes, including local recurrence and risk of distant metastasis, as well as overall survival (figure).1 Given that the estimated prognosis of patients with soft tissue sarcoma guides decisions on individual treatment concepts, patient counselling, and follow-up strategies,2 the accurate prediction of oncological outcomes is important. Fri, 01 May 2026 00:00:00 -0700
[Comment] Ionising radiation and cancer: a UN review of the recent epidemiological evidence In 2019, the UN Scientific Committee on the Effects of Atomic Radiation (UNSCEAR), whose mandate is to undertake scientific evaluations of the sources, effects, and risk of ionising radiation,1–3 convened a group of experts to review the latest epidemiological evidence on radiation and cancer risk. The updated report focuses on low-level radiation exposures; it has recently been approved and will be published in 2026.4 Fri, 01 May 2026 00:00:00 -0700
[Comment] Academic clinical cancer trials to improve patient outcomes Cancer clinical trials are conducted by both the commercial and non-commercial sectors. Whereas clinical trials conducted by the commercial sector aim for the marketing authorisation of new drugs, the primary characteristic of independent clinical trials conducted by the academic sector is the capacity to address a wide range of clinical research questions that are generally not addressed by the drug development industry. Crucial examples include the optimisation of surgical and radiation treatments, drug dose and treatment duration, multimodality combinations, sequence of treatments, head-to-head comparison of therapeutic strategies, better identification of patients who will or will not benefit, and addressing the needs of underserved patient populations. Fri, 01 May 2026 00:00:00 -0700
[Correspondence] CAR T-cell therapy at first relapse in myeloma We congratulate Hermann Einsele and colleagues on their phase 3 CARTITUDE-4 trial, a landmark study poised to reshape the therapeutic landscape of relapsed myeloma. By finding a significant overall survival advantage with ciltacabtagene autoleucel (cilta-cel) compared with pomalidomide–bortezomib–dexamethasone or daratumumab–pomalidomide–dexamethasone in patients with lenalidomide-refractory myeloma with one to three previous lines of therapy, CARTITUDE-4 provides compelling evidence that earlier use of CAR T-cell therapy can alter disease trajectory. Fri, 01 May 2026 00:00:00 -0700
[Correspondence] CAR T-cell therapy at first relapse in myeloma – Authors' reply We thank Jowon Laura Kim and S Vincent Rajkumar for their comments. Fri, 01 May 2026 00:00:00 -0700
[Correspondence] How flaws in study design and lead-time bias could affect the interpretation of data We read with interest the systematic review by C Tang and colleagues1 and compliment the authors for their comprehensive primary analysis of six randomised clinical trials (RCTs) comparing metastasis-directed therapy (MDT) with standard of care (SOC) in oligometastatic prostate cancer. However, we identified several important design concerns and methodological limitations that could compromise the validity and interpretation of the findings. Fri, 01 May 2026 00:00:00 -0700
[Correspondence] How flaws in study design and lead-time bias could affect the interpretation of data – Authors' reply We thank André Vis and Kim de Vries for their interest in our WOLVERINE study.1 We agree that, optimally, there will be well conducted phase III trials to inform the benefit of metastasis-directed therapy (MDT) for oligometastatic prostate cancer. However, these trials have yet to be reported, and in the interim, clinicians are left with an increasingly common clinical scenario that requires evidence-based direction. The highest-level data available are randomised phase 2 trials. However, heterogeneity exists between these trials given inherent differences and the timeframes over which they were run. Fri, 01 May 2026 00:00:00 -0700
[Corrections] Correction to Lancet Oncol 2026; 27: e218–30 Alger E, Regnault, A, Dueck AC, et al. A practical toolkit with recommendations for analysing and visualising patient-reported outcomes in early phase dose-finding oncology trials (OPTIMISE-AR). Lancet Oncol 2026; 27: e218–30—The appendix of this Policy View has been corrected as of April 27, 2026. Fri, 01 May 2026 00:00:00 -0700
[Corrections] Correction to Lancet Oncol 2026; 27: 461–69 Privé BM, Noordzij W, Muselaers CHJ, et al. [177Lu]Lu-PSMA-617 in oligometastatic hormone sensitive prostate cancer (BULLSEYE): an open-label, randomised, phase 2 study. Lancet Oncol 2026; 27: 461–69—In this Article, the title has been corrected to “[177Lu]Lu-PSMA-617 in oligometastatic hormone sensitive prostate cancer (BULLSEYE): an open-label, randomised, phase 2 study”. This correction has been made to the online version as of April 27, 2026. Fri, 01 May 2026 00:00:00 -0700
[News] Carcinogenicity of tris(chloropropyl) phosphate, butyraldehyde, and cumyl hydroperoxide In March, 2026, a Working Group of 12 scientists from nine countries met at the International Agency for Research on Cancer (IARC) in Lyon, France, to finalise their evaluation of the carcinogenicity of tris(chloropropyl) phosphate (TCPP), butyraldehyde, and cumyl hydroperoxide. Fri, 27 Mar 2026 08:00:04 +0000
[News] US oil blockade pushes Cuba's health system into crisis A US oil blockade causing several power blackouts in Cuba has led to tens of thousands of delayed surgeries while the health system tries to prioritise urgent care, including radiotherapy for 16 000 patients with cancer and chemotherapy for another 12 400 patients with cancer, say Cuban health authorities and the UN. Fri, 27 Mar 2026 23:30:01 +0000
[News] US cancer vaccines research at “tipping point” as NCI backs $200 million initiative The US National Cancer Institute (NCI) and the Foundation for the National Institutes of Health have launched a partnership to raise nearly US$200 million to fund clinical trials for cancer vaccines, including mRNA-based approaches for patients at high risk of tumour recurrence. Fri, 27 Mar 2026 23:30:01 +0000
[News] Senators demand explanation for US Preventive Services Task Force halt 19 US senators wrote to Health and Human Services Secretary Robert F Kennedy Jr on March 24, 2026, demanding he explain why the US Preventive Services Task Force (USPSTF)—the independent expert panel that has determined which cancer screenings and other preventive care Americans can access at no cost for four decades—has not met for a year. They called on Kennedy to submit an overdue, legally required annual USPSTF report to Congress, and to fill five vacancies among the 16 Task Force seats. Thu, 02 Apr 2026 22:30:01 +0000
[News] Canada's Yukon Territory publishes First Nations Cancer Strategy Canada's vast Yukon Territory in the country's northwest has published its first ever First Nations Cancer Strategy, aiming to improve cancer diagnosis, treatment, and care across the board for its First Nations people, who make up just less than 20% of the territory's population of around 48 000 people (2025 estimate). Some three-quarters of the population live in Whitehorse, the territory's capital near the southern border with the Province of British Colombia. Thu, 02 Apr 2026 22:30:03 +0000
[News] European Breast Cancer Conference 2026 Preliminary results of the ADARNAT pilot phase suggest that axillary radiotherapy (ART) without lymphadenectomy might safely replace axillary lymphadenectomy (ALND) in patients with limited node disease. Amparo Garcia-Tejedor (Hospital Universitari de Bellvitge, Gynecology, Hospitalet de Llobregat, Spain) presented results from the pilot phase of ADARNAT trial, an open-label, randomised, phase 3 multicentre trial across 23 Spanish hospitals. 272 patients with breast cancer (cT1–T4b, and cN0–cN1) treated with neoadjuvant therapy and 1–2 positive sentinel lymph nodes at surgery were randomly assigned to receive ART or ALND. Thu, 02 Apr 2026 22:30:01 +0000
[News] UK MHRA–NICE pathway to create faster regulatory approval A new aligned pathway has been established by the UK Medicines and Healthcare products Regulatory Agency (MHRA) and the National Institute for Health and Care Excellence (NICE) to facilitate earlier patient access to medicines, according to recently published guidance. Fri, 10 Apr 2026 22:30:01 +0000
[News] Trump's 2027 budget calls for further cuts to health research Medical groups are preparing to lobby Congress over health cuts proposed in the 2027 budget by the US Trump administration in the hope that lawmakers will ensure funding when spending plans are negotiated in the coming months. Thu, 16 Apr 2026 22:30:01 +0000
[Perspectives] CHEMO MAN—or how we used to remember It caught my attention one Sunday as I did inpatient rounds. Pinned to a corkboard, fading slightly at the edges, the drawing looked almost childish at first glance. A smiling stick figure labelled CHEMO MAN, organs sketched in block letters and arrows pointing outwards with names of drugs and toxicities carefully written in pen. Doxorubicin for the heart. Bleomycin for the lungs. Cisplatin for the kidneys. Methotrexate for the liver. Vincristine for the nerves. A mnemonic rendered as a body and, unintentionally, a theory of learning. Fri, 01 May 2026 00:00:00 -0700
[Perspectives] Turning breast cancer into art with Cancer Research UK On Jan 20–25, 2026, the Business Design Centre in London, UK, hosted the annual London Art Fair, which for the first time had Cancer Research UK (London, UK) as its official charity partner. Cancer Research UK, used their platform at the London Art Fair to showcase two artists whose lives have been affected by breast cancer. Tucked away in a quiet upstairs corner of the fair, slightly aside from the bustling central area, Cancer Research UK's relatively small exhibition displayed the works of Dr Helen Anahita Wilson and Carole Ellis, two revolutionary and incredibly talented artists and survivors of breast cancer. Fri, 01 May 2026 00:00:00 -0700
[Articles] Estimating total and diagnosed global cancer incidence and stage distribution from 1990 to 2050: a simulation-based analysis of 17 cancers These findings highlight the substantial and growing burden of cancers, especially in low-income and middle-income countries, where many people who develop cancer die undiagnosed. Accounting for demographic and epidemiological trends as well as health system factors, our modelling framework enables evaluation of targeted interventions to strengthen the cancer workforce and improve diagnostic pathways across diverse geographical and socioeconomic settings. Fri, 01 May 2026 00:00:00 -0700
[Articles] Estimating global cancer survival and mortality from 1990 to 2050: a simulation-based analysis of 17 cancers Disparities in global cancer survival are large and are expected to persist on current trends without transformative policy action. Our modelling framework provides comprehensive, country-level projections of survival and mortality for multiple cancers, accounting for demographic and epidemiological trends, as well as health system barriers and workforce constraints. Fri, 01 May 2026 00:00:00 -0700
[Articles] Estimating the impact of scaling up workforce personnel on global cancer mortality from 2030 to 2050: a simulation-based analysis of 17 cancers and 18 personnel types Investments to strengthen the cancer workforce will be essential to reduce global cancer mortality and improve timely diagnosis and survival. Strategic scale-up of personnel, particularly in diagnostics, alongside innovative strategies such as digital health solutions and role delegation, could result in substantial improvements in cancer outcomes. Policy makers should prioritise data-driven workforce planning as a crucial component of comprehensive cancer control strategies. Fri, 01 May 2026 00:00:00 -0700
[Articles] Safety and antitumour activity of ipatasertib combined with endocrine therapy and a CDK4/6 inhibitor in HR+/HER2– metastatic breast cancer (TAKTIC): a single-centre, open-label, phase 1b trial The combination of fulvestrant, ipatasertib, and palbociclib showed preliminary signs of clinical activity and showed expected adverse events in heavily pretreated patients with HR+/HER2– metastatic breast cancer, warranting further evaluation in those with CDK4/6 inhibitor-refractory disease. Fri, 01 May 2026 00:00:00 -0700
[Articles] CDK4/6 inhibitors plus endocrine therapy versus endocrine monotherapy in hormone receptor-positive, HER2-negative advanced breast cancer: a reconstructed individual patient data meta-analysis of phase 3 randomised controlled trials CDK4/6 inhibitors plus endocrine therapy significantly improved survival in hormone receptor-positive, HER2-negative advanced breast cancer. Benefits in progression-free survival and overall survival were consistent across major clinical subgroups. Although all agents improved progression-free survival, only ribociclib and abemaciclib showed statistically significant overall survival benefits, whereas palbociclib did not, and data for dalpiciclib remain immature. Further head-to-head comparisons and assessments of toxicity profiles, as well as patient-reported outcomes, are needed. Fri, 01 May 2026 00:00:00 -0700
[Articles] Lymph node surgery and CDK4/6 inhibitors in early breast cancer: a pooled analysis from five randomised trials Performing SLNB or cALND solely to determine eligibility for CDK4/6 inhibition requires very high number needed to diagnose and treat, adds substantial morbidity, and is costly, with only marginal overall survival benefit. Fri, 01 May 2026 00:00:00 -0700
[Articles] Pain and health-related quality-of-life outcomes with darolutamide in metastatic hormone-sensitive prostate cancer (ARANOTE): secondary and exploratory analyses of a multicentre, randomised, placebo-controlled, phase 3 trial Along with the known survival benefits, the clinically meaningful delays in pain progression and time to deterioration of overall wellbeing support consideration of darolutamide plus ADT as a standard-of-care treatment option in patients with mHSPC. Thu, 09 Apr 2026 22:30:01 +0000
[Articles] On-treatment serum prostate-specific antigen and overall survival in prostate cancer (STAMPEDE platform protocol): a post-hoc analysis of data from five phase 3 trials Metastatic volume or nodal status influence survival rates associated with on-treatment serum PSA categories, including for undetectable PSA. Radiological features and serum PSA could be combined to better predict survival. PSA at 24 weeks showed strongest associations with overall survival, although a PSA concentration of 0·2 ng/mL or less at any timepoint predicted favourable outcome. These findings could inform prognosis and warrant evaluation for treatment selection in clinical trials. Fri, 01 May 2026 00:00:00 -0700
[Articles] Bayesian sequential learning for prognostication in extremity soft tissue sarcoma (BayeSarc): a retrospective, multicentre cohort study BayeSarc is a continuously updatable, accurate, and precise prognostic tool for soft tissue sarcomas in the extremities. It reduces uncertainty, adapts to temporal changes, and refines variable weights. Its incorporation into the Sarculator app enables immediate clinical use, with potential to improve patient counselling, guide treatment decisions, and refine trial design. More broadly, the BSL framework provides an innovative and generalisable approach to prognostication in rare cancers, moving beyond the traditional two-step development–validation paradigm, enabling more efficient use of patient data. Fri, 01 May 2026 00:00:00 -0700
[Policy Review] Clinical trial endpoints for metastases-directed therapy in oligometastatic cancer: a review and Delphi consensus on behalf of the EORTC–ESTRO OligoCare consortium Oligometastatic cancer is characterised by a low volume of metastases to a small number of anatomical sites. However, evaluating the impact of metastases-directed therapies (MDTs) on overall survival or quality of life is often challenging. Current clinical trials use a wide range of primary endpoints that might not be validated or suited to MDT. To address this issue, we did a systematic review of international trial registries, alongside a Delphi consensus process involving 30 experts and five patient representatives. Fri, 01 May 2026 00:00:00 -0700
[Policy Review] International multisociety Delphi consensus for liver tumour thermal ablation: margin assessment This multisociety, multidisciplinary consensus—formally endorsed by the European Society of Surgical Oncology, the Cardiovascular and Interventional Radiological Society of Europe, and the Society of Interventional Oncology—was developed to standardise the assessment of ablation margins in liver tumour thermal ablation. A modified Delphi process, consisting of two online surveys and a hybrid (online and in-person meeting in Innsbruk) consensus meeting of 72 experts from North America, South America, Europe, and Asia. Fri, 01 May 2026 00:00:00 -0700
[Policy Review] International multisociety Delphi consensus for liver tumour thermal ablation: procedural and practice standards Thermal ablation offers a safer, less invasive, and more cost-effective curative-intent treatment for selected patients with primary and metastatic liver tumours than surgery; when done with appropriate technique, ablation can deliver similar oncological outcomes. However, effectiveness in routine practice varies because structured training, planning, and procedural governance remain scarce. These international multidisciplinary, multi-society guidelines—formally endorsed by the European Society of Surgical Oncology, the Cardiovascular and Interventional Radiological Society of Europe, and the Society of Interventional Oncology—define key domains contributing to procedural difficulty and practice variation in liver tumour thermal ablation. Fri, 01 May 2026 00:00:00 -0700
|
The importance of studying sex and gender in cancer research: Why and how
Thu, 07 May 2026 02:42:11 -0700 Clonal hematopoiesis in patients with cancer and cancer survivors: From clonal burden to cardiovascular diseases Wed, 06 May 2026 04:21:29 -0700 Prognostic impact of ASXL1 mutations in acute myeloid leukemia treated with lower intensity therapy Collectively, these findings suggest that ASXL1MUT AML may be more appropriately classified as intermediate risk in the context of LIT+VEN–based therapy, with the depth of impact influenced by the specific LIT backbone. Wed, 06 May 2026 04:04:55 -0700 Issue Information Wed, 06 May 2026 04:01:30 -0700 |
Survival of Patients Diagnosed With Cancer During the COVID-19 Pandemic
This cohort study investigates the association of the COVID-19 pandemic with short-term survival among patients diagnosed with cancer in 2020 and 2021 using US population-based cancer registry data. Salvage Focal Therapy vs Radical Prostatectomy for Localized Radiorecurrent Prostate Cancer This cohort study compares cancer control and perioperative complications among patients after salvage focal therapy vs salvage radical prostatectomy. Treatment of Follicular Lymphoma With CHOP and Anti-CD20 Therapy: 15-Year Follow-Up of the SWOG S0016 Trial This secondary analysis examines 15-year follow-up data from a randomized clinical trial to evaluate the potential for long-term remission and cure for follicular lymphoma following chemoimmunotherapy with cyclophosphamide, hydroxydaunorubicin/doxorubicin, oncovin, and prednisone/prednisolone (CHOP)–based regimens. Ancestry-Associated Performance Variability of Open-Source AI Models for EGFR Prediction in Lung Cancer This cohort study evaluated the performance and generalizability of 2 open-source artifical intelligence models in predicting mutations in Adjuvant Imatinib or Observation in Patients With Gastrointestinal Stromal Tumors With KIT Exon 9 Mutations This cohort study evaluates the association between adjuvant imatinib and recurrence-free survival and overall survival in patients with resected high-risk gastrointestinal stromal tumors (GISTs) with BrECADD vs BEACOPP and Health-Related Quality of Life in Advanced-Stage Hodgkin Lymphoma This secondary analysis of the GHSG HD21 randomized clinical trial evaluates the tolerability and impact of BrECADD vs escalated BEACOPP on health-related quality of life for patients with Hodgkin lymphoma. Cardiovascular Events in Women With Prior Cervical High-Grade Squamous Intraepithelial Lesion This cohort study examines cardiovascular disease risk, incidence, and mortality among adolescents and young adults with cervical high-grade squamous intraepithelial lesions (HSILs). Pericardial Effusion and Bruton Tyrosine Kinase Inhibitors in B-Cell Malignant Disease This cohort study examines the association of bruton tyrosine kinase inhibitor therapy in B-cell malignant disease with increased risk of pericardial effusion and cardiovascular outcomes. New Retroperitoneal Soft-Tissue Lesion in Multiple Myeloma A 67-year-old man with a history of λ light-chain multiple myeloma presents with increased serum-free λ light chain levels. What is your diagnosis? Making Veterans Visible in National Cancer Registries This Viewpoint discusses improving US cancer surveillance systems to address veteran-specific risks and outcomes. The Time for Cancer Vaccines Is Now: Advancing Toward Lasting Cancer Immunity This Viewpoint discusses advances in cancer vaccines, including the use of COVID-19 pandemic–related infrastructure, clinical trial results, and harnessing artificial intelligence. Cancer Research and Public Health Literacy—Making Sense This Viewpoint examines the challenges and strategies for improving public health literacy related to cancer research and care, including effective communication and ethical engagement among researchers, health care professionals, and patients. Risk-Based Screening for Breast Cancer: Time to Focus on Implementation Lessons From the SONIA Trial on Timing of CDK4/6 Inhibitors in Advanced Breast Cancer—The Sooner, the Better? Redefining Salvage Therapy for Localized Radiorecurrent Prostate Cancer—In More Ways Than One Taking Care of Your Mouth During Cancer Treatment This Between Ambition and Duty—A Path That I Did Not Choose This essay describes a turn of events that compelled a medical oncology fellow to learn to care for young patients with sarcoma and to rediscover why he chose medicine in the first place. Meeting the Mirror Prostate-Specific Membrane Antigen PET-Guided Salvage Radiotherapy—Precision or Prematurity? Prostate-Specific Membrane Antigen PET-Guided Salvage Radiotherapy—Precision or Prematurity?—Reply Risk Factors for Valvulopathy Among Childhood Cancer Survivors Risk Factors for Valvulopathy Among Childhood Cancer Survivors—Reply Competing Risk of Death in Heart Failure or Cardiomyopathy Prediction After Breast Cancer Competing Risk of Death in Heart Failure or Cardiomyopathy Prediction After Breast Cancer—Reply Physical Activity, Lifestyle, and Cancer Risk Physical Activity, Lifestyle, and Cancer Risk—Reply Cribriform-Positive and -Negative Prostate Cancer Cribriform-Positive and -Negative Prostate Cancer—Reply JAMA Oncology |
|
|
| |||
|
[Editorial] Mental health at the heart of haematology
May is a time to elevate mental health awareness. In the USA, May is designated as Mental Health Awareness Month; Europe marks Mental Health Week (May 4–8); and the UK observes Mental Health Awareness Week (May 11–17). These events invite a renewed collective focus on connection, resilience, and hope for the more than one billion people worldwide who live with mental health conditions, placing a substantial burden on individuals and health systems. Yet, our understanding of mental health within the fields of haematology and haematological oncology remains limited. Fri, 01 May 2026 00:00:00 -0700
[Comment] Two decades of phase 1 and 2 trials in relapsed or refractory diffuse large B-cell lymphoma Since the year 2000, the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) have authorised many novel cancer therapies based on phase 1–2 single-arm trials.1,2 Most of these were granted as conditional marketing authorisations (EMA) or Accelerated Approvals (FDA), which aim to provide early access to promising therapies in diseases with high unmet medical need. Acknowledging that single-arm trials can show biological activity but cannot reliably establish whether an experimental treatment is better than the current standard, these approvals are contingent on demonstration of clinical benefit in subsequent confirmatory randomised trials. Fri, 01 May 2026 00:00:00 -0700
[In Focus] Leveraging TikToks in clinical practice TikToks (short vertical videos) are increasingly infiltrating our lives, as well as those of our patients. In mid-2020, TikTok was one of the fastest growing social media platforms, with over half a billion active users and with TikToks also routinely viewed on other social media platforms or shared directly by friends and family. Armed with this knowledge, in my role as Director of the donor recruitment organisation Stem Cell Club, I led the development of a library of TikToks to engage young adults to stem-cell donation. Fri, 01 May 2026 00:00:00 -0700
[In Focus] From enrolment to authorship: racial and global disparities in phase 3 multiple myeloma clinical trials Clinical trials in multiple myeloma continue to fail populations most affected by the disease, with Black individuals remaining profoundly underrepresented in the studies that define contemporary treatment standards. Multiple myeloma is the second most common haematological malignancy, and the incidence, prevalence, and disability-adjusted life years attributable to the disease have increased over time, with mortality rates remaining high. Despite this burden, the therapeutic landscape of multiple myeloma has been transformed by the development of novel agents evaluated in clinical trials, resulting in substantial improvements in survival and meaningful gains in quality of life. Fri, 01 May 2026 00:00:00 -0700
[Articles] Very early [18F]FDG-PET-guided targeted therapy in untreated advanced-stage classic Hodgkin lymphoma (EORTC-1537-COBRA): primary results of a single-arm, multicentre, phase 2 trial Very early PET-guided intensification with BrECADD yields high activity in advanced-stage classic Hodgkin lymphoma while sparing most patients intensive chemotherapy. Fri, 01 May 2026 00:00:00 -0700
[Articles] Safety and activity of pirtobrutinib in patients with relapsed or refractory Waldenström macroglobulinaemia: 5-year follow-up of the open-label, multicentre, phase 1/2 BRUIN trial Pirtobrutinib was highly active and well tolerated, regardless of previous exposure to covalent BTK inhibitors, and might be a promising new therapeutic option for patients with relapsed or refractory Waldenström macroglobulinaemia, particularly in those previously exposed to covalent BTK inhibitors, for whom durable and effective treatments are needed. Fri, 01 May 2026 00:00:00 -0700
[Articles] Risks and benefits for patients with relapsed or refractory diffuse large B-cell lymphoma in early-phase clinical trials: a systematic review and meta-analysis Since the year 2000, early-phase trials in relapsed or refractory diffuse large B-cell lymphoma have shown more than a doubling of response rates, driven primarily by cellular and bispecific antibody therapies, while maintaining low treatment-related mortality. These results provide risk-benefit trends in early-phase trials and define contemporary benchmarks for clinicians, investigators and regulators. Fri, 01 May 2026 00:00:00 -0700
[Articles] Final results of nilotinib versus nilotinib combined with pegylated interferon alfa-2a as first-line therapy in chronic phase chronic myeloid leukaemia in France (PETALs): an open-label, multicentre, randomised phase 3 trial In this setting, Peg-IFN combined with nilotinib induced higher initial rates of MR4·5 compared to TKI monotherapy, despite additional side effects. The onset of psychiatric events might promote immediate cease of Peg-IFN and psychiatrist advice Whether this early molecular response translates into sustained treatment-free survival should be studied in a randomised trial sufficiently powered for this outcome. Fri, 01 May 2026 00:00:00 -0700
[Review] Who will watch the watchmen: unique challenges of T-cell redirecting therapies in T-cell malignancies The development of novel T-cell redirecting immune therapies—including immune checkpoint inhibitors, bispecific antibodies, chimeric antigen receptor T cells, and virus-specific T cells—represents a major advancement in the treatment of haematological malignancies. Although such therapies have strong evidence for efficacy in the treatment of B-cell neoplasms, several unique challenges are encountered when using these therapies for the treatment of T-cell malignancies. In this Review, we discuss the application of T-cell modulating immune therapies in T-cell neoplasms, with a focus on the complicated bidirectional interactions between malignant and bystander T cells in disease pathogenesis, and the resultant challenges affecting the design and deliverability of T-cell modulating therapies in this cohort. Fri, 03 Apr 2026 22:30:00 +0000
[Review] Guidelines for the management of acute porphyria: recommendations from the International Porphyria Network Autosomal dominant acute porphyrias are rare inherited disorders of haem biosynthesis characterised by accumulation of potentially neurotoxic porphyrin precursors and attacks of severe abdominal pain with autonomic and neuropsychiatric features. Disease severity ranges from asymptomatic individuals to those with recurrent, life-threatening attacks. The International Porphyria Network invited 34 acute porphyria specialists from 17 countries to form an expert panel. The invited group included clinicians from diverse specialities (ie, internal medicine, haematology, endocrinology, gastroenterology, hepatology, neurology, and biochemistry), together with laboratory scientists and patient representatives. Fri, 01 May 2026 00:00:00 -0700
[Clinical Picture] An otherwise smouldering multiple myeloma with a solitary osteolytic lesion and soft-tissue mass A 69-year-old woman was referred to our department after monoclonal gammopathy was detected during routine testing. Her medical history included dyslipidaemia, hypothyroidism, and right hip replacement due to congenital dysplasia. Physical examination, complete blood count, and serum biochemical tests were unremarkable. Immunofixation revealed monoclonal IgGλ (total IgG 1060 mg/dL), with a normal free light chain (FLC) ratio. Urine immunofixation was negative. A bone marrow biopsy showed 12% clonal plasma cell infiltration, consistent with smouldering multiple myeloma (SMM) pending whole-body, low-dose CT (WBLD–CT). Thu, 02 Apr 2026 22:30:01 +0000
[Clinical Picture] Protein-losing enteropathy in marginal zone lymphoma: tissue is the issue A 67-year-old woman was diagnosed with nodal marginal zone lymphoma with IgMκ paraproteinaemia, circulating monoclonal B cells, multifocal lymph node involvement (MYD88WT), and splenomegaly. Rituximab monotherapy yielded partial metabolic remission on PET–CT and an IgM concentration decrease from 15·4 g/L to 12·4 g/L (normal range: 0·4–2·3 g/L). However, the patient reported severe progressive diarrhoea (up to 50 times per day). A 13 kg weight loss resulted in total parenteral nutrition dependence. Fri, 01 May 2026 00:00:00 -0700
|
MRD testing in Hodgkin lymphoma: filling the knowledge gaps
Volume 147, Issue 19 May 7 2026 Is gene therapy a cure for β-thalassemia? Volume 147, Issue 19 May 7 2026 Making the case for ruxolitinib in CAR T-cell enterocolitis Volume 147, Issue 19 May 7 2026 Focusing a sPOTlight on POT1 Volume 147, Issue 19 May 7 2026 Adding transcriptomic features to MF prognostic models Volume 147, Issue 19 May 7 2026 A tale of two transferrin receptors Volume 147, Issue 19 May 7 2026 Generational advancement of factor VIIIa mimetics Volume 147, Issue 19 May 7 2026 Myeloid/lymphoid neoplasms with FGFR1 rearrangement and pemigatinib Volume 147, Issue 19 May 7 2026 Dual-antigen–targeting T-cell immunotherapies in MM: circumventing tumor heterogeneity and preventing antigen escape Volume 147, Issue 19 May 7 2026 MRD-2 in the GHSG HD21 trial assessed by a validated circulating tumor DNA sequencing assay Using a case-cohort design, Heger and colleagues evaluated the applicability of circulating tumor DNA (ctDNA) sequencing to assess minimal residual disease (MRD) in patients with Hodgkin lymphoma (HL) enrolled in the GHSH HD21 trial following 2 cycles of treatment (MRD-2). They show that MRD-2–negative patients exhibit a lower risk of progression, relapse, or death and that combining MDR-2 with positron emission tomography and computed tomography scans after 2 cycles improves identification of patients at low and high risk of progression, relapse, and death.
Volume 147, Issue 19 May 7 2026 Long-term efficacy and safety results of betibeglogene autotemcel gene therapy for transfusion-dependent β-thalassemia Transfusion-dependent β-thalassemia (TDT) requires rigorous, lifelong transfusion therapy and iron chelation to manage iron overload. Betibeglogene autotemcel gene therapy uses mobilized autologous peripheral blood stem CD34+ cells transduced with a lentiviral vector encoding a modified functional adult β-globin gene hemoglobin. Kwiatkowski and colleagues report on the long-term efficacy and safety of this gene therapy in 63 patients with TDT, documenting sustained transfusion independence for up to 10 years and a safety profile consistent with that of myeloablative autologous transplantation.
Volume 147, Issue 19 May 7 2026 Ruxolitinib for ciltacabtagene autoleucel–associated refractory diarrhea Intractable diarrhea is a recently described serious complication that can occur after BCMA-targeted chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma (MM), with reported mortality rates of 36% to 50%. Blumenberg and colleagues present a single-center retrospective case series of 5 patients who developed severe diarrhea concerning for immune-mediated enterocolitis after ciltacabtagene autoleucel therapy. They show that diarrhea is driven by apparent CAR T-cell activity in the gut, with potential clonal evolution into CAR T cell–associated indolent T-cell lymphoproliferative disease of the gastrointestinal tract.
Volume 147, Issue 19 May 7 2026 Lymphoid malignancy and clonality in the POT1-mediated long telomere syndrome If telomeres are abnormally long, cells have extended life spans and have increased in vitro replicative capacity, allowing accumulation of DNA changes that can lead to cancer. Davidson-Swinton and colleagues present a large cohort of 51 individuals from 24 families with heterozygous deleterious germ line variants in POT1, a gene that determines telomere length, and describe the cancers developed in over 2652 lifetime-years. Age itself is the most important predictor of cancer development, with almost all people older than 60 in the study having at least 1 cancer diagnosis. Mutant POT1 predisposes to a pan–lymphoid malignancy syndrome affecting 45% of people in the study by the age of 80 and is also associated with melanoma, sarcoma, and myeloproliferative neoplasms.
Volume 147, Issue 19 May 7 2026 A stem and progenitor cell–derived gene expression signature is prognostic for survival in myelofibrosis Prior studies demonstrated that transcriptomic profiles could predict survival in myelofibrosis (MF). By applying single-cell RNA sequencing data derived from Lin-CD34+ MF stem and progenitor cells (HSPCs) from 358 patients with MF, Medeiros and colleagues identified a gene expression–based prognostic score for survival, the MPN24, calculated by using the weighted expression values of 24 HSPC-derived genes. Patients clustering in the MPN24-high group had significantly worse 5-year survival than those in the MPN24-low group, and the model was validated in 2 independent cohorts. Prospective validation will be critical to determine the clinical practice applicability and usefulness of this new score.
Volume 147, Issue 19 May 7 2026 Tfr2 is necessary for acute iron-dependent hepcidin induction in mice with Tfr1-deficient hepatocytes Transferrin receptors (TfRs) play critical roles in cellular iron uptake and iron sensing; however, their roles in hepatocytes are incompletely understood. By generating mice with hepatocyte-specific deletion of Tfrc (encoding TfR1), Tfr2, or both, Liu et al demonstrate that TfR1 and TfR2 exert partially nonoverlapping functions to regulate the iron hormone hepcidin and systemic iron homeostasis under basal conditions. This study and this novel animal model establish the basis for future mechanistic studies on the regulation of hepcidin and the pathogenesis of hemochromatosis.
Volume 147, Issue 19 May 7 2026 NXTAGE: a phase 1/2 study of NXT007 to assess safety, pharmacokinetics, and efficacy in hemophilia A without inhibitors Bispecific antibody treatment has revolutionized the treatment of hemophilia. Nogami and colleagues report the results of a phase 1/2 nonrandomized multiple-escalating-dose trial of a novel activated factor VIII (FVIIIa) mimetic bispecific antibody, NXT007, administered subcutaneously once a month. In a study of 30 emicizumab-naive patients with severe hemophilia A, they show persistent levels of hemostasis (>40 IU of FVIII per dL) with the higher NXT007 doses following monthly delivery, excellent clinical efficacy, and absence of significant adverse events. Collectively, the results of this study are promising and provide strong evidence of excellent clinical outcomes with infrequent drug administration.
Volume 147, Issue 19 May 7 2026 Time of infusion does not significantly impact outcomes following CAR T-cell therapy in large B-cell lymphoma Volume 147, Issue 19 May 7 2026 Classic Hodgkin lymphoma with IGH::CCND1 rearrangement: evidence of clonal relation to preceding mantle cell lymphoma Volume 147, Issue 19 May 7 2026 |
Post CAR‐T Measurable Residual Disease Monitoring in Mantle Cell Lymphoma Enables Early Detection of Disease Relapse
Mon, 04 May 2026 03:00:56 -0700 Pathogenic PF4/Polyanion ELISA‐Negative Antibodies in HIT Sat, 02 May 2026 00:41:03 -0700 The Association of Age and Frailty With Adverse Events for Bortezomib and Carfilzomib: A Population‐Based Analysis Thu, 30 Apr 2026 21:00:30 -0700 Prognostic Value of Hypoxemia for Acute Chest Syndrome in Adults With Sickle Cell Disease Wed, 29 Apr 2026 22:19:46 -0700 NGS‐Driven Digital PCR for Personalized and Accurate Measurable Residual Disease Assessment in Acute Myeloid Leukemia Wed, 29 Apr 2026 22:00:24 -0700 Massive Neutrophil Necrobiosis due to Colchicine Toxicity Wed, 29 Apr 2026 04:58:51 -0700 Hydroxyurea Delays the Onset of Hyposplenism in Young Children With Sickle Cell Disease Mon, 27 Apr 2026 18:54:33 -0700 Outcomes With First‐Line PD1 Inhibitors in Extranodal NK/T‐Cell Lymphoma: A Comparative Analysis From a 755‐Patient Multicenter Cohort Sun, 26 Apr 2026 18:54:55 -0700 Multicenter Real‐World Analysis of Glofitamab in Relapsed/Refractory Primary CNS Lymphoma: Clinical Activity, CNS Penetration, and ctDNA Dynamics Sat, 25 Apr 2026 22:35:33 -0700 Hyper‐CVAD Versus Hyper‐CVAD Plus Blinatumomab With or Without Inotuzumab Ozogamicin for Adult Patients With Newly Diagnosed Philadelphia Chromosome‐Negative Acute Lymphoblastic Leukemia: A Propensity‐Score Analysis Sat, 25 Apr 2026 21:49:20 -0700 Cladribine With Low‐Dose Cytarabine and Venetoclax Alternating With Azacitidine and Venetoclax for Newly Diagnosed Acute Myeloid Leukemia Sat, 25 Apr 2026 21:15:17 -0700 Blinatumomab and Ponatinib Versus Hyper‐CVAD and Ponatinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome‐Positive Acute Lymphoblastic Leukemia: A Propensity Score Analysis Fri, 24 Apr 2026 18:55:39 -0700 Mind the Gap: Underdosing of Intravenous Iron in a Hospitalized Patient Population With Iron‐Deficiency Anemia Fri, 24 Apr 2026 05:25:21 -0700 Real‐World Outcomes of FLAG‐Ida Regimen in 1079 Adult Patients With First Relapsed/Refractory AML: A PETHEMA Study Wed, 22 Apr 2026 00:00:00 -0700 A Novel Plasma Heme Assay Reveals Disease Severity in Beta‐Thalassemia and Sickle Cell Anemia Wed, 22 Apr 2026 00:00:00 -0700 The Emerging Role of Liver Stiffness Measurement in Transfusion Dependent Thalassemia Tue, 21 Apr 2026 21:11:18 -0700 Integrating Recent Evidence and Expert Perspectives Into the Management of Multiple Myeloma: Consensus Recommendations From the 2025 Bridging the Gaps Conference Tue, 21 Apr 2026 20:45:10 -0700 Long‐Term Quality of Life in 1777 Persons With Hodgkin Lymphoma and 6166 Matched Comparators Sat, 18 Apr 2026 08:05:45 -0700 Autoimmune and Inflammatory Diseases in Polycythemia Vera and Essential Thrombocythemia: Impact on Disease Outcomes and Comorbidities Fri, 17 Apr 2026 23:36:01 -0700 High‐Altitude Hypoxemia in Adults With Sickle Cell Disease (SCD) Fri, 17 Apr 2026 23:29:53 -0700 Mixed Type Autoimmune Hemolytic Anemia: Clinical Severity and Treatment Patterns in a Large Observational Study Fri, 17 Apr 2026 21:10:36 -0700 |
|
|
| |||
|
Vein-to-vein data: what predicts platelet response? April 28 2026 - Volume 10, Issue 8 Reconsidering GVHD prophylaxis in cord blood transplantation April 28 2026 - Volume 10, Issue 8 Aging cells, young patients: senescence in Hodgkin lymphoma April 28 2026 - Volume 10, Issue 8 Hypertension and CLL: a common and hazardous relationship April 28 2026 - Volume 10, Issue 8 Finding the genes that fit CPX-351 April 28 2026 - Volume 10, Issue 8 Investigative reporting on factor VIII whereabouts April 28 2026 - Volume 10, Issue 8 Understanding the impact of social determinants of health in hematology: a scoping review of trends across journals and over time April 28 2026 - Volume 10, Issue 8 High concordance of physician-attestation with manual data abstraction for sickle cell type: an ASH RC Data Hub study April 28 2026 - Volume 10, Issue 8 Pregnancy after hematopoietic stem cell transplant: an international multicenter study April 28 2026 - Volume 10, Issue 8 Acquired nonpermissive BM microenvironment impairs HSC proliferation and maintenance, and B-cell development after HSCT April 28 2026 - Volume 10, Issue 8 Alloantibody IgG subclasses have differential activity in clearing transfused platelets in mice April 28 2026 - Volume 10, Issue 8 CCR4 expression defines a targetable subset of T-cell acute lymphoblastic leukemia April 28 2026 - Volume 10, Issue 8 An indirect comparison of zanubrutinib vs acalabrutinib plus venetoclax in patients with treatment-naive CLL April 28 2026 - Volume 10, Issue 8 Disordered differentiation and cellular senescence in pediatric Hodgkin Reed-Sternberg cells April 28 2026 - Volume 10, Issue 8 Hypertension affects survival and treatment in chronic lymphocytic leukemia April 28 2026 - Volume 10, Issue 8 Incidence, timing, and prognosis of heart failure after treatment for large B-cell lymphoma in Sweden during 2007-2022 April 28 2026 - Volume 10, Issue 8 Allogeneic HSCT for consolidation in pediatric refractory or relapsed ALK-positive anaplastic large cell lymphoma April 28 2026 - Volume 10, Issue 8 A novel approach to defining progression in MDS and precursor myeloid conditions in the MDS Natural History Study April 28 2026 - Volume 10, Issue 8 Baseline IPSS-M vs pretransplant risk downstaging as prognostic determinants in MDS undergoing allogeneic transplantation April 28 2026 - Volume 10, Issue 8 CPX-351 selectively benefits patients with AML and myelodysplasia-related mutations in the pivotal randomized trial April 28 2026 - Volume 10, Issue 8 IMS-IMWG 2025 consensus genomic staging predicts outcomes with daratumumab-based quadruplet regimens for NDMM April 28 2026 - Volume 10, Issue 8 Allogeneic hematopoietic cell transplantation for aplastic anemia: a single institution experience across 6 decades April 28 2026 - Volume 10, Issue 8 Sickle cell vaso-occlusive episodes correlate with the magnetic heterogeneity of red blood cells April 28 2026 - Volume 10, Issue 8 Factor VIII originates primarily from anatomically distinct subsets of liver sinusoidal endothelial cells April 28 2026 - Volume 10, Issue 8 Associations of blood donor and product characteristics with platelet transfusion outcomes April 28 2026 - Volume 10, Issue 8 GVHD prophylaxis after cord blood transplantation in patients with high-risk AML: a nationwide Japanese cohort study April 28 2026 - Volume 10, Issue 8 The role of HLA transcription in unrelated hematopoietic cell transplantation April 28 2026 - Volume 10, Issue 8 Tildrakizumab for the prophylaxis of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation April 28 2026 - Volume 10, Issue 8 Vestibular symptoms after talquetamab therapy in heavily pretreated multiple myeloma April 28 2026 - Volume 10, Issue 8 Ibrutinib or non-BTK inhibitor therapy in relapsed Waldenström macroglobulinemia: a real-life multicenter Italian study April 28 2026 - Volume 10, Issue 8 Age-associated hematopoietic variants in the rhesus macaque April 28 2026 - Volume 10, Issue 8 Development of an integrated clinical-laboratory scoring system for accurate HIT diagnosis April 28 2026 - Volume 10, Issue 8 Strategies employed to facilitate representativeness in hematology clinical research: a survey of ASH investigators April 28 2026 - Volume 10, Issue 8 Exploring the role of blinatumomab in pediatric B-lymphoblastic lymphoma (B-LLy) April 28 2026 - Volume 10, Issue 8 PNH extravascular hemolysis: exploring clinical significance April 28 2026 - Volume 10, Issue 8 |
American Society of Hematology/International Society on Thrombosis and Haemostasis 2024 updated guidelines for treatment of venous thromboembolism in pediatric patients Blood Adv (2025) 9 (10): 2587–2636. ASH Clinical Practice Guidelines: strategies to stay up-to-date Blood Adv (2023) 7 (21): 6707–6709. American Society of Hematology, ABHH, ACHO, Grupo CAHT, Grupo CLAHT, SAH, SBHH, SHU, SOCHIHEM, SOMETH, Sociedad Panamena de Hematología, Sociedad Peruana de Hematología, and SVH 2023 guidelines for diagnosis of venous thromboembolism and for its management in special populations in Latin America Blood Adv (2023) 7 (13): 3005–3021. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis for patients with COVID-19: March 2022 update on the use of anticoagulation in critically ill patients Blood Adv (2022) 6 (17): 4975–4982. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: January 2022 update on the use of therapeutic-intensity anticoagulation in acutely ill patients Blood Adv (2022) 6 (17): 4915–4923. American Society of Hematology, ABHH, ACHO, Grupo CAHT, Grupo CLAHT, SAH, SBHH, SHU, SOCHIHEM, SOMETH, Sociedad Panameña de Hematología, Sociedad Peruana de Hematología, and SVH 2022 guidelines for prevention of venous thromboembolism in surgical and medical patients and long-distance travelers in Latin America Blood Adv (2022) 6 (12): 3636–3649. The ASH-ASPHO Choosing Wisely Campaign: 5 hematologic tests and treatments to question Blood Adv (2022) 6 (2): 679–685. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: July 2021 update on postdischarge thromboprophylaxis Blood Adv (2022) 6 (2): 664–671. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: May 2021 update on the use of intermediate-intensity anticoagulation in critically ill patients Blood Adv (2021) 5 (20): 3951–3959. American Society of Hematology 2021 guidelines for sickle cell disease: stem cell transplantation Blood Adv (2021) 5 (18): 3668–3689. ASH, ABHH, ACHO, Grupo CAHT, Grupo CLAHT, SAH, SBHH, SHU, SOCHIHEM, SOMETH, Sociedad Panameña de Hematología, SPH, and SVH 2021 guidelines for management of venous thromboembolism in Latin America Blood Adv (2021) 5 (15): 3032–3046. Methodology for adaptation of the ASH Guidelines for Management of Venous Thromboembolism for the Latin American context Blood Adv (2021) 5 (15): 3047–3052. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer Blood Adv (2021) 5 (4): 927–974. American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19 Blood Adv (2021) 5 (3): 872–888. ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease Blood Adv (2021) 5 (1): 301–325. ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease Blood Adv (2021) 5 (1): 280–300. American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults Blood Adv (2020) 4 (15): 3528–3549. American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain Blood Adv (2020) 4 (12): 2656–2701. Methodology for the American Society of Hematology VTE guidelines: current best practice, innovations, and experiences Blood Adv (2020) 4 (10): 2351–2365. |
Efficacy and Safety of an mRNA Seasonal Influenza Vaccine in Adults
New England Journal of Medicine, Volume 394, Issue 18, Page 1803-1813, May 7, 2026.
Base Editing of HBG1 and HBG2 Promoters for Sickle Cell Disease New England Journal of Medicine, Volume 394, Issue 18, Page 1824-1835, May 7, 2026.
Daraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cancer New England Journal of Medicine, Volume 394, Issue 18, Page 1790-1802, May 7, 2026.
Antithrombotic Therapy after Ablation for Atrial Fibrillation New England Journal of Medicine, Volume 394, Issue 18, Page 1868-1872, May 7, 2026.
Reducing Bacterial Contamination of Blood Bags with a Double Knot New England Journal of Medicine, Volume 394, Issue 18, Page 1865-1866, May 7, 2026.
Advances in RAS Therapeutics for Pancreatic Cancer New England Journal of Medicine, Volume 394, Issue 18, Page 1857-1861, May 7, 2026.
Immune Interference New England Journal of Medicine, Volume 394, Issue 18, Page 1847-1853, May 7, 2026.
Erythema Multiforme New England Journal of Medicine, Volume 394, Issue 18, May 7, 2026.
Meet the Equation New England Journal of Medicine, Volume 394, Issue 18, May 7, 2026.
From Mission to Margin in Academic Medicine — The Impact of Corporate Medicine on Medical Training New England Journal of Medicine, Volume 394, Issue 18, Page 1769-1772, May 7, 2026.
Reforming Payment for Clinician-Administered Drugs — Most-Favored-Nation Pricing in Medicare Part B New England Journal of Medicine, Volume 394, Issue 18, Page 1774-1777, May 7, 2026.
Prehospital Whole Blood in Traumatic Hemorrhage — a Randomized Controlled Trial New England Journal of Medicine, Ahead of Print.
Sirolimus-Coated Balloon Angioplasty for Infrainguinal Artery Disease New England Journal of Medicine, Ahead of Print.
Intravascular Ultrasound–Guided or Angiography-Guided Complex High-Risk PCI New England Journal of Medicine, Ahead of Print.
Iptacopan in IgA Nephropathy — Final 24-Month Data New England Journal of Medicine, Ahead of Print.
Mavacamten in Adolescents with Obstructive Hypertrophic Cardiomyopathy New England Journal of Medicine, Ahead of Print.
A Phase 3 Trial of Brepocitinib in Dermatomyositis New England Journal of Medicine, Ahead of Print.
Efficacy and Safety of Obinutuzumab in Active Systemic Lupus Erythematosus New England Journal of Medicine, Ahead of Print.
Pulsed Field Ablation as Initial Therapy for Persistent Atrial Fibrillation New England Journal of Medicine, Ahead of Print.
Human Infection with Highly Pathogenic Avian Influenza A(H5N5) Virus New England Journal of Medicine, Ahead of Print.
Seeing the Left Main Coronary Artery Clearly — Is IVUS Always Necessary? New England Journal of Medicine, Ahead of Print.
Toward Broader Adoption of Coronary Physiological Assessment New England Journal of Medicine, Ahead of Print.
Stenting for Post-Thrombotic Syndrome — A Step Forward New England Journal of Medicine, Ahead of Print.
|
|
|
| |||
|
|
BCMA-targeted bispecific antibodies in relapsed/refractory multiple myeloma: three approvals, many questions
Volume 31, Issue 6, June 2026, oyag165 Shifting a paradigm: highlights of model informed drug development in dosage selection and optimization for oncology products Volume 31, Issue 6, June 2026, oyag154 Trends in primary surgery and overall survival in non-metastatic anal cancer: a population-based analysis Volume 31, Issue 6, June 2026, oyag148 Predictive factors for early mortality after regorafenib or trifluridine/tipiracil initiation in metastatic colorectal cancer Volume 31, Issue 6, June 2026, oyag142 Resilience in symptom response to cancer treatment: a new lens for examining variable symptom trajectories in older adults with advanced cancer Volume 31, Issue 6, June 2026, oyag094 Characterization and clinical management of adverse events following treatment with repotrectinib: a TRIDENT-1 analysis Volume 31, Issue 6, June 2026, oyag137 Exploring biologically-based complementary and alternative medicine use among Irish cancer survivors: findings from a national survey Volume 31, Issue 6, June 2026, oyag127 Tumor growth rate as an intermediate trial endpoint Volume 31, Issue 6, June 2026, oyag149 |
The Price of Free Advice Diseases of the Colon & Rectum.69(5):733-735, May 2026. What Every Colorectal Surgeon Should Know About the Centers for Medicare and Medicaid Services Age-Friendly Hospital Measure Diseases of the Colon & Rectum.69(5):736-740, May 2026. Rupert B. Turnbull Jr, M.D., American Society of Colon and Rectal Surgeons President and Founder of The Cleveland Clinic Department of Colorectal Surgery Diseases of the Colon & Rectum.69(5):741-749, May 2026. Total and Tailored Mesorectal Excision for Rectal Cancer: Origins, Evolution, and Misconceptions Diseases of the Colon & Rectum.69(5):750-754, May 2026. Shared Decision-Making in Locally Advanced Rectal Cancer Diseases of the Colon & Rectum.69(5):755-758, May 2026. Expert Commentary on Shared Decision-Making in Rectal Cancer Diseases of the Colon & Rectum.69(5):759, May 2026. Stoma-Free Survival Following Low Anterior Resection With Coloanal Anastomosis for Stage II and III Rectal Cancer Diseases of the Colon & Rectum.69(5):760-767, May 2026. Utility of Transanal Total Mesorectal Excision in Patients With Obesity and Mid-to-Low Rectal Cancer: A Single-Center, Retrospective Cohort Study Diseases of the Colon & Rectum.69(5):768-777, May 2026. Biologics Before Surgery Are Not Associated With Complications After Surgery for IBD: A National Surgery Quality Improvement Program IBD Collaborative Causal Inference Analysis Diseases of the Colon & Rectum.69(5):778-791, May 2026. Treatment of Anal Fistula in Crohn’s Disease With Platelet-Rich Plasma: Long-term Results Diseases of the Colon & Rectum.69(5):792-800, May 2026. Patterns and Outcomes of Treatment Failure After Ligation of Intersphincteric Fistula Tract for Cryptoglandular Anal Fistula: Analysis of 200 Failed Ligation of the Intersphincteric Fistula Tract Cases Diseases of the Colon & Rectum.69(5):801-808, May 2026. Preliminary Results of Open Excisional Hemorrhoidectomy Combined With 3% Polidocanol Foam Sclerotherapy in Patients With Grade IV Hemorrhoidal Disease: A Randomized Controlled Open-Label Single-Center Study Diseases of the Colon & Rectum.69(5):809-818, May 2026. Autologous Platelet-Rich Plasma in Complex Anal Fistula Treatment: Getting It Right? Promising Clinical Data From 90 Patients Diseases of the Colon & Rectum.69(5):819-825, May 2026. Complications and Readmissions in Diverting Loop Ileostomies and Loop Colostomies Diseases of the Colon & Rectum.69(5):826-835, May 2026. Can Large Language Models Be a Viable Tool for Consensus Working Groups? Experience of the Ventral Rectopexy Expert Consensus Group Diseases of the Colon & Rectum.69(5):836-846, May 2026. Selected Abstracts Diseases of the Colon & Rectum.69(5):847-851, May 2026. Single-Port Robotic Abdominoperineal Resection and Bulky Lateral Lymph Node Dissection Via a Trans-stoma Site Approach Diseases of the Colon & Rectum.69(5):852-853, May 2026. From Instability to Strength: The “Laparoscopic Triple Compartment Sling” Solution for Multiple Compartmental Prolapse Diseases of the Colon & Rectum.69(5):854-855, May 2026. Laparoscopic Approach for Total Proctocolectomy With Ileoanal Pouch Reconstruction for Familial Polyposis Coli Diseases of the Colon & Rectum.69(5):856-857, May 2026. Remodified Hanley Technique for Horseshoe Abscess Diseases of the Colon & Rectum.69(5):858, May 2026. |
|
|
| |||
|
FDA Approves Zenocutuzumab-zbco for Advanced, Unresectable, or Metastatic Cholangiocarcinoma
On May 8, 2026, the U.S. Food and Drug Administration (FDA) approved the HER2- and HER3–directed bispecific antibody, zenocutuzumab-zbco (Bizengri), for adults with advanced, unresectable or metastatic cholangiocarcinoma harboring a neuregulin 1 (NRG1) gene fusion with disease progression on or... Long-Term Outcomes With Maintenance Rucaparib in Advanced Pancreatic Cancer With BRCA or PALB2 Pathogenic Variants In an analysis of a single-center trial reported in a research letter in JAMA Oncology, Reiss et al identified long-term outcomes with rucaparib maintenance in patients with platinum-sensitive advanced pancreatic ductal adenocarcinoma (PDAC) with BRCA1, BRCA2, or PALB2 germline or somatic... Tiragolumab/Atezolizumab and Chemotherapy Fails in Advanced Nonsquamous NSCLC As reported in JAMA Oncology by Socinski et al, the phase III SKYSCRAPER-06 trial showed no progression-free or overall survival benefit with tiragolumab, a monoclonal antibody targeting T-cell immunoreceptor with Ig and ITIM domains (immunoreceptor tyrosine-based inhibitory motifs) (TIGIT), plus... Appendiceal Cancer: Serum Tumor Marker Levels May Guide Treatment in Patients Undergoing Cytoreductive Surgery A retrospective study found that levels of commonly measured serum tumor markers—CEA, CA19-9, and CA125—can play a significant role in predicting outcomes in patients with appendiceal adenocarcinoma undergoing cytoreductive surgery (CRS), with or without hyperthermic intraperitoneal chemotherapy... Thursday, May 7, 2026 11:24 AM High YAP1 Expression Leads to Chemotherapy Resistance, Relapse in Treated SCLC Expression of the YAP1 protein following treatment with chemotherapy is associated with the development of treatment resistance and cancer relapse in patients with small cell lung cancer (SCLC), according to findings from an analysis published in Journal of Thoracic Oncology. The researchers... Thursday, May 7, 2026 10:30 AM AI Pathology Framework for Biological Understanding of Tumors An agentic artificial intelligence (AI) framework may help researchers gain a better understanding of hidden biological information of tumors, according to a study published in Nature Medicine. Wednesday, May 6, 2026 12:30 PM AI Model Enables Earlier Detection of Pancreatic Cancer on Routine CT Scans In a landmark study published in Gut, Mukherjee et al developed and validated the Radiomics-based Early Detection Model (REDMOD), an automated artificial intelligence (AI) framework that identifies subtle, preclinical imaging signatures of pancreatic ductal adenocarcinoma on routine computed... Breast Density Reduction: Endoxifen vs Tamoxifen Low doses of the investigational agent endoxifen reduced breast density to the same extent as the standard treatment tamoxifen, with fewer adverse events, according to results from the KARISMA study, a proof-of-principle, dose-determining, double-blinded, randomized, placebo-controlled trial. These ... Wednesday, May 6, 2026 11:59 AM Advanced CKM Syndrome Associated With Greater Cancer Risk Advanced cardiovascular-kidney-metabolic (CKM) syndrome may be associated with an increased risk of developing cancer, according to findings from a Japanese study published in Circulation: Population Health and Outcomes. Tuesday, May 5, 2026 1:00 PM Integrated Molecular Analysis Identifies Determinants of Outcomes in TP53-Mutated DLBCL In a study reported in the Journal of Clinical Oncology, Uppal et al identified factors associated with poorer outcomes in patients with TP53-mutated diffuse large B-cell lymphoma (DLBCL). Adjuvant Hepatic Arterial Infusion After Surgery for Colorectal Liver Metastases In a French phase II trial (PACHA-01) reported in the Journal of Clinical Oncology, Gelli et al found that adjuvant hepatic infusion of oxaliplatin improved hepatic recurrence–free survival vs intravenous (IV) oxaliplatin, both combined with fluorouracil/leucovorin (LV5FU2), after curative-intent... Targeted Therapies Drive Long-Term Decline in Multiple Myeloma Mortality in the United States Investigators used data from the Surveillance, Epidemiology, and End Results (SEER) database to analyze trends in multiple myeloma mortality in the United States from 1975 to 2023. Their findings were published in Oncotarget. Tuesday, May 5, 2026 10:38 AM AI Shows Dermatologist-Level Accuracy in Melanoma Diagnosis but Needs Validation In a systematic review and meta-analysis published in JAMA Dermatology, Laiouar-Pedari et al evaluated the real-world diagnostic performance of artificial intelligence (AI)–assisted dermoscopy for melanoma detection. The study was undertaken to address a critical gap in the literature: while prior... CLL Linked to Increased Skin Cancer Risk and Mortality In a nationwide population–based cohort study reported in JAMA Dermatology, Blomberg Drejøe et al evaluated the long-term risk of skin cancer and related outcomes among patients with chronic lymphocytic leukemia (CLL). By leveraging comprehensive Danish health registries, the investigators aimed to ... COA and Flatiron Health Study Finds Patients May Experience Longer Survival in Community Oncology Settings Patients diagnosed with metastatic breast cancer and non–small cell lung cancer (NSCLC) had longer survival compared to national benchmarks when treated in independent community oncology practices, according to a new study commissioned by the Community Oncology Alliance (COA) and conducted by... Monday, May 4, 2026 12:51 PM Zoldonrasib in Patients With KRAS G12D–Mutant NSCLC Previously Treated With Chemoimmunotherapy The investigational KRAS G12D inhibitor zoldonrasib had a favorable safety profile and induced antitumor activity in some patients with KRAS G12D–mutated non–small cell lung cancer (NSCLC) who were previously treated with chemotherapy and immunotherapy, according to preliminary findings from an... Monday, April 20, 2026 12:00 PM Early-Onset ICI-Related Myocarditis Linked to Increased Mortality Early-onset of immune checkpoint inhibitor (ICI)–related myocarditis was associated with an increased risk for myocarditis fatality, according to the results of a study presented at the American Association for Cancer Research (AACR) Annual Meeting 2026 (Abstract 5212). The researchers suggested... Wednesday, April 22, 2026 11:45 AM Atezolizumab in Alveolar Soft Part Sarcoma: Long-Term Follow-up As reported in the Journal of Clinical Oncology by Chen et al, extended follow-up of the pivotal phase II trial of atezolizumab in patients with alveolar soft part sarcoma (ASPS) showed continued benefit of atezolizumab treatment. FDA Permits Expanded Access for Investigational Pancreatic Cancer Drug On May 1, the U.S. Food and Drug Administration announced that it issued a “safe to proceed” letter to Revolution Medicines, allowing the sponsor to initiate an expanded access treatment protocol (EAP) for its experimental pancreatic cancer drug, daraxonrasib. Monday, May 4, 2026 12:37 PM Four-Drug Regimen Induces High Complete Response Rate in Early-Stage Classical Hodgkin Lymphoma High objective response and complete response rates were observed with treatment with brentuximab vedotin and nivolumab in combination with doxorubicin and dacarbazine chemotherapy in patients with early-stage classical Hodgkin lymphoma, according to the results of a phase II trial published in Monday, May 4, 2026 12:00 PM On-Treatment PSA and Overall Survival in Prostate Cancer In a post hoc analysis reported in The Lancet Oncology, Kayani et al found that on-treatment prostate-specific antigen (PSA) level was associated with overall survival in patients with metastatic or very high-risk nonmetastatic prostate adenocarcinoma from five phase III trials in the STAMPEDE... FDA Approves Vepdegestrant for ER-Positive, HER2-Negative, ESR1-Mutated Advanced Breast Cancer On May 1, the U.S. Food and Drug Administration (FDA) approved vepdegestrant (Veppanu), a heterobifunctional protein degrader, for the treatment of adult patients with estrogen receptor (ER)-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized ... Friday, May 1, 2026 2:00 PM Melanoma: Gut Microbiome May Help Predict Recurrence After Immunotherapy Gut bacterial markers may be able to predict recurrence in patients with high-risk melanoma receiving adjuvant immune checkpoint inhibition, according to study findings published in Cell. Friday, May 1, 2026 11:30 AM Association of Body Size and Bladder Cancer Risk In a study—The Pooling Project of Prospective Studies of Diet and Cancer—reported in the Journal of Clinical Oncology, Milne et al in the National Cancer Institute Cohort Consortium found that increased body size is associated with increased risk of bladder cancer among men, but not among women. Lenalidomide Plus Rituximab in Relapsed or Refractory Indolent Non-Hodgkin Lymphoma: 5-Year Follow-up From AUGMENT As reported in the Journal of Clinical Oncology by Leonard et al, the 5-year follow-up of the phase III AUGMENT trial has shown continued benefit of lenalidomide plus rituximab (R2) vs rituximab with placebo (R-placebo) in patients with relapsed or refractory indolent non-Hodgkin lymphoma. Can PFAS Exposure Raise ALL Risk? Early exposure to per- and polyfluoroalkyl substances (PFAS), a group of widely used compounds known as “forever chemicals,” may be associated with a higher risk of developing acute lymphoblastic leukemia (ALL), according to findings published by Vieira et al in the Journal of Exposure Science... Friday, May 1, 2026 11:34 AM |
Sex-related differences in dynamic right ventricular-pulmonary vascular coupling in heart failure with preserved ejection fraction Right ventricle (RV) dysfunction is associated with poorer outcomes in heart failure with preserved ejection fraction (HFpEF). Females are more likely to have HFpEF but males have worse prognosis and resting RV function. The contribution of dynamic RV-pulmonary artery (RV-PA) coupling between sex and its impact on peak exercise capacity (VO2) in HFpEF is not known. Thu, 31 Dec 2020 20:15:06 -0800 Phase II Investigation of the efficacy of Antimycobacterial therapy in Chronic Pulmonary Sarcoidosis A Phase I, single-center investigation demonstrated that 8 weeks of antimycobacterial therapy improved sarcoidosis forced vital capacity (FVC). Safety and efficacy assessments have not been performed in a multicenter cohort. Wed, 30 Dec 2020 20:15:06 -0800 Medical Education During the COVID-19 Pandemic All aspects of medical education were affected by the Novel Coronavirus Infectious Disease-19 (COVID-19) pandemic. Several challenges were experienced by trainees and programs alike due to the economic repercussions of the pandemic, how social distancing affected the delivery of medical education, testing and interviewing, how the surge of patients affected redeployment of personnel, potential compromise in core training and the overall impact on the wellness and mental health of trainees and educators. Tue, 29 Dec 2020 20:15:06 -0800 Impact of Bronchiectasis on incident NTM pulmonary disease: A 10-Year national cohort study Sat, 26 Dec 2020 20:15:06 -0800 Categorized Priority Systems: A New Tool for Fairly Allocating Scarce Medical Resources in the Face of Profound Social Inequities Fri, 25 Dec 2020 20:15:06 -0800 Impact of Right Ventricular Dysfunction on Short- and Long-Term Mortality in Sepsis: A Meta-Analysis of 1,373 Patients In this meta-analysis of observational studies, RV dysfunction was associated with higher short-term and long-term mortality in sepsis and septic shock. Wed, 23 Dec 2020 20:15:06 -0800 RESEARCH LETTER: Pulmonary function and risk of Alzheimer dementia: two-sample Mendelian randomization study Mon, 21 Dec 2020 20:15:06 -0800 “We usually don’t vote on intubation.” Mon, 21 Dec 2020 20:15:06 -0800 Risk factors, management, and outcomes of legionella pneumonia in a large nationally-representative sample Legionella is an uncommon cause of CAP, occurring primarily from late spring through early autumn. Testing is uncommon, even among patients with risk factors, and many positive patients failed to receive empiric coverage for LP. Sat, 19 Dec 2020 20:15:06 -0800 Which N descriptor is more predictive of prognosis in resected non-small cell lung cancer: the number of involved nodal stations versus the location-based pathological N stage? The nS classification could be used to provide a more accurate prognosis in patients with resected NSCLC. The nS is worth taking into consideration when defining nodal category in the forthcoming ninth edition of the staging system. Sat, 19 Dec 2020 20:15:06 -0800 Identifying and characterizing a chronic cough cohort through electronic health records NLP successfully identified a large cohort with CC. Most patients were identified through NLP alone, rather than diagnoses or medications. NLP improved detection of patients nearly seven-fold, addressing the gap in ability to identify and characterize CC disease burden. Nearly all cases appeared to be managed in primary care. Identifying these patients is important for characterizing treatment and unmet needs. Thu, 17 Dec 2020 20:15:06 -0800 Development and validation of algorithms to identify pulmonary arterial hypertension in administrative data Pulmonary arterial hypertension (PAH) is a rare disease and much of our understanding stems from single-center studies, which are limited by sample size and generalizability. Administrative data offer an appealing opportunity to inform clinical, research, and quality improvement efforts for PAH. Yet, there is currently no standardized, validated method to distinguish PAH from other subgroups of pulmonary hypertension (PH) within this data source. Thu, 17 Dec 2020 20:15:06 -0800 Development and Prospective Validation of a Deep Learning Algorithm for Predicting Need for Mechanical Ventilation A transparent DL algorithm improves on traditional clinical criteria to predict the need for MV in hospitalized patients, including in those with COVID-19. Such an algorithm may help clinicians optimize timing of tracheal intubation, better allocate resources and staff, and improve patient care. Thu, 17 Dec 2020 20:15:06 -0800 The clinical use of lung MRI in cystic fibrosis: what, now, how? To assess airway and lung parenchymal damage non-invasively in cystic fibrosis (CF), chest MRI has been historically out of the scope of routine clinical imaging due to technical difficulties such as the low proton density and respiratory and cardiac motion. However, technological breakthroughs have recently emerged to dramatically improve lung MRI quality (including signal-to-noise ratio, resolution, speed, contrast). At the same time, novel treatments have changed the landscape of CF clinical care. Thu, 17 Dec 2020 20:15:06 -0800 Endobronchial Valves for the Treatment of Advanced Emphysema Bronchoscopic lung volume reduction with one-way endobronchial valves is a guideline treatment option for patients with advanced emphysema, supported by extensive scientific data. Patients limited by severe hyperinflation, with a suitable emphysema treatment target lobe and with absence of collateral ventilation are the responders to this treatment. Detailed patient selection, a professional treatment performance, and dedicated follow-up of the valve treatment, including management of complications, are key ingredients to success. Thu, 17 Dec 2020 20:15:06 -0800 “How I Do It: Nurse Coordinator Roles and Responsibilities for Bronchoscopic Lung Volume Reduction with Endobronchial Valves” Chronic Obstructive Pulmonary Disease (COPD) may cause profound dyspnea, functional impairment, and reduced quality of life. Available pharmacologic therapy provides suboptimal symptom improvement in many patients. Bronchoscopic lung volume reduction (BLVR), achieved with endobronchial valve (EBV) placement, can effectively improve dyspnea and functional status in appropriately selected patients. Operationalizing a safe and effective BLVR program requires appropriate oversight which can be achieved by a BLVR Nurse Coordinator (NC). Tue, 15 Dec 2020 20:15:06 -0800 Oncology Care Provider (OCP) Training in Empathic Communication Skills to Reduce Lung Cancer Stigma Empathy-based, stigma-reducing communication may lead to improved assessments of tobacco use and smoking cessation for patients with smoking-related cancers. These findings support the dissemination and further testing of a new ECS model for training OCPs in best practices for assessment of smoking history and engagement of patients who currently smoke in tobacco treatment delivery. Tue, 15 Dec 2020 20:15:06 -0800 Clinical outcomes and healthcare resource utilization associated with reslizumab treatment in adults with severe eosinophilic asthma in real-world practice In clinical practice, reslizumab may have been initiated in response to heavy symptom burden and CAEs. Reslizumab was associated with improved clinical and patient-reported outcomes and significant reductions in asthma-related HRU. Mon, 14 Dec 2020 20:15:06 -0800 Decreasing case-fatality but not mortality rate following admission to intensive care units in Australia, 2005-2018. Mon, 14 Dec 2020 20:15:06 -0800 Quantitative Emphysema on Low-Dose Computed Tomography of the Chest and Risk of Lung Cancer and Airflow Obstruction: An analysis of the National Lung Screening Trial Quantitative emphysema measured on LDCT of the chest can be leveraged to improve lung cancer risk prediction and help diagnose COPD in individuals who currently or formerly smoked undergoing lung cancer screening. Mon, 14 Dec 2020 20:15:06 -0800 |
Liquid biopsy to inform adjuvant decisions during neoadjuvant chemotherapy — a full-circle moment for nasopharyngeal cancer
The historical development of plasma Epstein–Barr virus DNA for informing clinical decisions for patients with nasopharyngeal carcinoma has culminated in the EP-STAR trial. The circulating tumour DNA clearance patterns observed during neoadjuvant chemotherapy could be used to guide adjuvant therapy, improve outcomes and possibly reflect differences in tumour biology. Herein we discuss why this study constitutes a full-circle moment and provides valuable insights for advancing circulating tumour DNA-based applications in precision oncology. Wed, 06 May 2026 00:00:00 -0700 The transformative role of SBRT in the management of spinal metastases Spinal metastases are associated with debilitating pain and neurological deterioration as well as a poor prognosis and have historically been managed with a palliative intent. Now, following the emergence of stereotactic body radiotherapy (SBRT), more effective pain control as well as control of the metastatic lesions is becoming feasible. In this Review, the authors describe the development and role of SBRT in the management of spinal metastases. Tue, 05 May 2026 00:00:00 -0700 Synergistic integration of regional and systemic therapies in uveal melanoma Treatments for metastatic uveal melanoma utilize various liver-directed strategies, yet optimal integration with systemic therapy is unclear. Here we examine recent evidence indicating that combining percutaneous hepatic perfusion with immune-checkpoint inhibitors might improve patient outcomes, compare it with data from other trials and highlight key questions around patient selection, sequencing and mechanisms that will shape future strategies. Wed, 29 Apr 2026 00:00:00 -0700 Emerging trends in the global burden of colorectal cancer The incidence of colorectal cancer (CRC) has historically been the highest among Western, high-income countries but is now increasing globally beyond these regions. Early-onset CRC (diagnosed before the age of 50 years) has been the main driver of this rise, and risk factors including dietary and lifestyle aspects, the gut microbiota and environmental contaminants have been proposed to underlie these epidemiological trends. The authors of this Review discuss the available evidence on these risk factors, highlighting how the under-representation of non-Western populations in these studies is limiting progress. Tue, 28 Apr 2026 00:00:00 -0700 The clinical landscape of HIF2α inhibitors in oncology Long considered undruggable, hypoxia-inducible factor 2α (HIF2α) has now been validated as a therapeutic target in several cancers. This Review discusses the structural basis for HIF2α druggability, the clinical results to date and key challenges, including toxicities and the need for predictive biomarkers, as well as emerging targeting modalities and combination strategies that might enhance efficacy, overcome resistance and broaden indications for HIF2 inhibition. Tue, 28 Apr 2026 00:00:00 -0700 Did ATOMIC really improve on the standard of care for mismatch repair-deficient colon cancer? The ATOMIC trial has been widely celebrated as providing a positive result. However, when viewed with a lens of critical appraisal that considers issues related to overtreatment, treatment de-escalation, surrogacy, post-trial access to treatment and contributions of component, we argue that ATOMIC should not change clinical practice but rather form the basis for future trials that test de-escalation strategies. Thu, 23 Apr 2026 00:00:00 -0700 Systemic induction therapy and the expanding frontier of bladder preservation in MIBC Two recent phase II trials, INDIBLADE and SURE-02, challenge the long-standing paradigm of mandatory radical local therapy for muscle-invasive bladder cancer (MIBC). As increasingly potent systemic induction treatment strategies emerge, a key question arises: can induction therapy response guide omission of radical surgery and radiotherapy to enable preservation of an intact, functioning bladder in selected patients? Wed, 22 Apr 2026 00:00:00 -0700 Time as an unmeasured ‘dose’ in oncology: introducing time budgeting as a design principle for cancer care The burden of cancer therapy on patients’ time is often overlooked. Building on the ‘time toxicity’ literature, we introduce the concept of time budgeting, viewing patients’ time as a limited, measurable resource that can be managed through treatment selection, pathway design and trial protocols. We discuss the rationale, measurement challenges and implementation requirements to operationalize time budgeting in cancer care. Tue, 21 Apr 2026 00:00:00 -0700 |
|
|
| |||
|
Predictive model based on folate receptor-positive circulating tumor cells in neoadjuvant immunochemotherapy for esophageal cancer
Vol 17, No 2 (April 30, 2026): Neoadjuvant adebrelimab combined with triplet chemotherapy for locally advanced resectable adenocarcinoma of esophagogastric junction: a prospective, single-arm, phase II feasibility and safety study Vol 17, No 2 (April 30, 2026): The prevalence of gastric intestinal metaplasia in the Saudi population: a single-tertiary center retrospective study Vol 17, No 2 (April 30, 2026): Prognostic impact of low absolute skeletal muscle mass 6 months after gastrectomy for gastric cancer: a retrospective cohort study Vol 17, No 2 (April 30, 2026): Diagnostic value of mini-probe endoscopic ultrasound in preoperative tumor nodal (TN) staging of gastric cancer and analysis of factors influencing T-staging accuracy Vol 17, No 2 (April 30, 2026): Transcatheter arterial embolization with N-butyl cyanoacrylate versus gelatin sponge particles for gastric cancer-related upper gastrointestinal bleeding: a comparison of efficacy and safety Vol 17, No 2 (April 30, 2026): Postoperative frailty among elderly patients undergoing radical surgery for gastrointestinal tumors and its relationship with prognosis Vol 17, No 2 (April 30, 2026): Molecular characteristics and metastatic mechanism of patients diagnosed with Krukenberg tumor from gastric cancer Vol 17, No 2 (April 30, 2026): Retrospective study on clinical outcomes and safety evaluation of da Vinci robot-assisted laparoscopy and endoscopic cooperative for small gastric stromal tumors resection: preliminary single-center experience Vol 17, No 2 (April 30, 2026): The impact of ulinastatin on postoperative clinical outcomes in patients with gastric cancer: a retrospective cohort analysis Vol 17, No 2 (April 30, 2026): Comparison of the efficacy and safety of single-incision versus multi-port laparoscopic D2 lymphadenectomy for locally advanced gastric cancer: a systematic review and meta-analysis Vol 17, No 2 (April 30, 2026): Development and external validation of a prognostic nomogram for cancer-specific survival in elderly patients with early-stage gastric cancer Vol 17, No 2 (April 30, 2026): Identification of immunogenic cell death-related prognostic genes in gastric cancer Vol 17, No 2 (April 30, 2026): Opportunistic CT screening for osteosarcopenia predicts reduced overall survival in patients with gastric cancer: a retrospective cohort study Vol 17, No 2 (April 30, 2026): Patterns of recurrence and outcomes of poor responders to neoadjuvant long-course chemoradiotherapy for rectal cancer Vol 17, No 2 (April 30, 2026): Identification of an autophagy-related prognostic signature and validation of WDR45 in colorectal cancer Vol 17, No 2 (April 30, 2026): KRAS mutation subtypes refine prognostic stratification in colorectal cancer: a retrospective cohort study Vol 17, No 2 (April 30, 2026): Development and validation of manganese metabolism-related genes prognostic model in colorectal cancer and its immunological characteristics Vol 17, No 2 (April 30, 2026): Intratumoral PKM2 expression predicts benefit from adjuvant FOLFOX in stage II–III colorectal cancer Vol 17, No 2 (April 30, 2026): Assessment of colorectal cancer recurrence risk following solid organ transplantation Vol 17, No 2 (April 30, 2026): CCL5 promotes colon cancer progression via PI3K/AKT signaling and is negatively regulated by STAT1 Vol 17, No 2 (April 30, 2026): Molecular subtyping and prognostic model construction based on endosome-related genes in colorectal cancer Vol 17, No 2 (April 30, 2026): No survival benefit from adjuvant chemotherapy in high-risk stage II small intestinal adenocarcinoma after surgery: a population-based long-term survival analysis Vol 17, No 2 (April 30, 2026): Transarterial embolization combined with octreotide long-acting release in treating rectal neuroendocrine tumor liver metastases: a single-institutional experience Vol 17, No 2 (April 30, 2026): Single-cell transcriptome analysis identifies neutrophil-related prognostic signatures in hepatocellular carcinoma Vol 17, No 2 (April 30, 2026): TRNP1 regulates tumorigenesis and enhances immunotherapy response via c-Kit/STAT3 signaling in hepatocellular carcinoma Vol 17, No 2 (April 30, 2026): Perioperative clinicopathologic model for predicting 12-month early recurrence after curative hepatectomy in hepatocellular carcinoma Vol 17, No 2 (April 30, 2026): Association of serum lactate dehydrogenase levels with the severity of microvascular invasion in hepatocellular carcinoma: a retrospective cross-sectional study Vol 17, No 2 (April 30, 2026): An exploratory nomogram model with 18F-FDG PET/CT metabolic parameters for predicting high-risk status of microvascular invasion in hepatocellular carcinoma patients prior to liver transplantation Vol 17, No 2 (April 30, 2026): Impact of tumor mutation burden on the prognosis of patients with unresectable hepatocellular carcinoma undergoing transcatheter arterial chemoembolization combined with immunotherapy and anti-angiogenic drugs Vol 17, No 2 (April 30, 2026): Prognostic genes in hepatocellular carcinoma and their function: an analysis integrating high-throughput-based spatial transcriptomics and single-cell RNA-sequencing Vol 17, No 2 (April 30, 2026): PD-1 inhibitors combined with tyrosine kinase inhibitors for conversion therapy in patients with unresectable hepatocellular carcinoma: a retrospective cohort study Vol 17, No 2 (April 30, 2026): Development and validation of a model for predicting short-term complications after hepatectomy in patients with primary liver cancer Vol 17, No 2 (April 30, 2026): Temporal change in liver function after stereotactic body radiation therapy for hepatocellular carcinoma Vol 17, No 2 (April 30, 2026): A novel deep learning and radiomics approach based on DCE-MRI for predicting the P53 mutation status in hepatocellular carcinoma Vol 17, No 2 (April 30, 2026): Peripheral regulatory T cells trajectory predicts progression-free survival in hepatocellular carcinoma patients during on-demand transarterial chemoembolization using joint model: a prospective study Vol 17, No 2 (April 30, 2026): PD-1/PD-L1 expression and predictive value of efficacy in hepatocellular carcinoma patients with anti-PD-1 therapy: a real-world study Vol 17, No 2 (April 30, 2026): Indeterminate nodule-like arterial phase hyperenhancement in the liver on CT: differentiation of hepatocellular carcinomas from vascular pseudolesions using a CT radiomics approach Vol 17, No 2 (April 30, 2026): Association between primary tumor resection and survival in metastatic intrahepatic cholangiocarcinoma: a retrospective cohort study based on the SEER database Vol 17, No 2 (April 30, 2026): Multi-scale deep learning models based on MRI for predicting pathological differentiation and evaluating its association with recurrence-free survival in hepatocellular carcinoma: an explainable machine learning study Vol 17, No 2 (April 30, 2026): Daily increment of residual liver regeneration (DIRER) predicts tumor recurrence and mortality after radical hepatectomy for hepatocellular carcinoma Vol 17, No 2 (April 30, 2026): Silencing OTUB1 induces pyroptosis to inhibit the growth of liver cancer HepG2 cells via the NLRP3/caspase/GSDM signaling pathway Vol 17, No 2 (April 30, 2026): Targeting AKR1C1 overcomes lenvatinib resistance in hepatocellular carcinoma through the STAT3-ABC transporters pathway Vol 17, No 2 (April 30, 2026): Multi-institutional care is associated with improved survival in biliary tract cancer Vol 17, No 2 (April 30, 2026): Development and validation of machine learning models integrating spectral computed tomography-derived three-dimensional quantitative parameters for predicting histopathological grade in pancreatic ductal adenocarcinoma Vol 17, No 2 (April 30, 2026): A biomarker-integrated nomogram for predicting postoperative pancreatic fistula in low- to intermediate-risk patients after pancreaticoduodenectomy Vol 17, No 2 (April 30, 2026): Impact of preoperative body weight on short-term and long-term prognosis after pancreatic resection for pancreatic ductal adenocarcinoma: a multicenter study Vol 17, No 2 (April 30, 2026): A TRPM4-associated necrotic cell death signature for prognostic stratification in pancreatic cancer Vol 17, No 2 (April 30, 2026): Single-nucleus RNA sequencing reveals the effects of key regulators on human pancreatic adenocarcinoma and its tumor microenvironment Vol 17, No 2 (April 30, 2026): Neoadjuvant radiotherapy after chemotherapy does not improve surgical or survival outcomes in borderline resectable pancreatic cancer Vol 17, No 2 (April 30, 2026): A systematic review of artificial intelligence and machine learning for gut microbiome-based CRC screening Vol 17, No 2 (April 30, 2026): Multimodal data-driven prediction of postoperative recurrence and survival in hepatocellular carcinoma: a narrative review Vol 17, No 2 (April 30, 2026): Risk factors for exclusive lung metastasis in colorectal cancer: a comprehensive narrative review Vol 17, No 2 (April 30, 2026): Advances in mitophagy research in hepatocellular carcinoma: mechanisms and therapeutic implications Vol 17, No 2 (April 30, 2026): A case report of rectal squamous cell carcinoma following radiation therapy for prostate cancer: a management dilemma Vol 17, No 2 (April 30, 2026): Diagnostic challenges in gastrointestinal stromal tumors: a case report of concurrent gastrointestinal stromal tumor, lymphangioma, and solid pseudopapillary neoplasm of the pancreas Vol 17, No 2 (April 30, 2026): Brain metastasis from KRAS wild-type pancreatic cancer and organoid correlates: a case report Vol 17, No 2 (April 30, 2026): Gastric lymphoma presenting with predominant pancreatitis and cranial neuropathy: a rare clinical presentation—a case report Vol 17, No 2 (April 30, 2026): A case report of gastroesophageal adenocarcinoma with yolk sac tumor differentiation in a pregnant patient Vol 17, No 2 (April 30, 2026): The underestimated global burden and projections of early-onset stomach and early-onset esophageal cancers Vol 17, No 2 (April 30, 2026): Impact of maintenance therapy with fluoropyrimidines in advanced esophageal-gastric adenocarcinoma: a critical review Vol 17, No 2 (April 30, 2026): Methodological clarifications on maintenance fluoropyrimidines in advanced esophagogastric adenocarcinoma: a real-world Mexican cohort Vol 17, No 2 (April 30, 2026): Fruquintinib in refractory metastatic colorectal cancer: separating randomized trial evidence from observational data Vol 17, No 2 (April 30, 2026): Interpreting the evidence base for fruquintinib in refractory metastatic colorectal cancer Vol 17, No 2 (April 30, 2026): Biomarker-guided immuno-angiogenic therapy in biliary tract cancer: insights from IMbrave151 Vol 17, No 2 (April 30, 2026): Personalised neoadjuvant therapy, based on tumour characteristics and patient choice, is the best way forward in rectal cancer Vol 17, No 2 (April 30, 2026): Is FOLFIRINOX more effective than gemcitabine plus nab-paclitaxel in pancreatic adenocarcinoma? —a decade of debate! Vol 17, No 2 (April 30, 2026): Emerging mechanisms of kinase inhibitor escape and clinical implications of ponatinib in advanced gastrointestinal stromal tumor Vol 17, No 2 (April 30, 2026): When precision medicine meets human behavior: limits of artificial intelligence in predicting imatinib adherence Vol 17, No 2 (April 30, 2026): Anlotinib plus penpulimab: a new contender in first-line therapy for unresectable hepatocellular carcinoma Vol 17, No 2 (April 30, 2026): Muscling in on body surface area to reduce oxaliplatin-induced peripheral neuropathy in colon cancer Vol 17, No 2 (April 30, 2026): Clearing the bar: adding anti-VEGF therapy to chemoimmunotherapy for biliary tract cancer Vol 17, No 2 (April 30, 2026): Maximizing the “toolbox” for patients with initially unresectable colorectal liver metastases: have liver mets “met” their match? Vol 17, No 2 (April 30, 2026): The 12-node rule in irradiated rectal cancer: time for reappraisal? Vol 17, No 2 (April 30, 2026): Beyond drug toxicity: the hidden burden of financial toxicity in hepatocellular carcinoma Vol 17, No 2 (April 30, 2026): Gastrointestinal malignancies in pregnancy: practical considerations Vol 17, No 2 (April 30, 2026): Intrahepatic cholangiocarcinoma: the equity gap in one of the most lethal cancers Vol 17, No 2 (April 30, 2026): Adjuvant chemotherapy in elderly colon cancer patients: when less may be more Vol 17, No 2 (April 30, 2026): Sarcopenia in esophageal cancer: from passive prognostic marker to active treatment target Vol 17, No 2 (April 30, 2026): Return on investment, return of risk: private equity in gastrointestinal cancer care Vol 17, No 2 (April 30, 2026): Tumor necrosis as a key refinement of risk stratification in gastric gastrointestinal stromal tumors Vol 17, No 2 (April 30, 2026): Survival outcomes in early gastric cancer: evidence from SEER-based population studies Vol 17, No 2 (April 30, 2026): Spontaneous rupture of hepatocellular carcinoma: mechanobiology, rescue, and oncologic control Vol 17, No 2 (April 30, 2026): From waste to wealth: malignant ascites-derived organoids as a compass for precision therapy in advanced gastrointestinal cancers Vol 17, No 2 (April 30, 2026): Erratum: Efficacy and safety of dose adjustment for fruquintinib in the third-line treatment of metastatic colorectal cancer: a retrospective study with real-world settings Vol 17, No 2 (April 30, 2026): Retraction: Interfering HMGB3 release from cancer-associated fibroblasts by miR-200b represses chemoresistance and epithelial-mesenchymal transition of gastric cancer cells Vol 17, No 2 (April 30, 2026): |
Step-by-Step Pancreaticoduodenectomy in Complete Situs Inversus: Technical Strategy to Preserve Oncologic Principles in a Rare Anatomical Setting
Fri, 08 May 2026 00:00:00 -0700 ASO Visual Abstract: Geographic Differences in Patient Experience after a Diagnosis of Lobular Breast Cancer Thu, 07 May 2026 00:00:00 -0700 ASO Visual Abstract: Neoadjuvant Therapy as a Selection Strategy for Curative Resection in High-Risk Intrahepatic Cholangiocarcinoma Thu, 07 May 2026 00:00:00 -0700 Modified FOLFIRINOX with or Without Stereotactic Body Radiation in Locally Advanced Unresectable Pancreatic Cancer (SABER): A Randomized Open-Label Phase 2 Trial Thu, 07 May 2026 00:00:00 -0700 Prognosis After Curative Resection of Esophageal Basaloid Squamous Cell Carcinoma: A Single-Institution Retrospective Study Thu, 07 May 2026 00:00:00 -0700 PneumoScore: Risk Prediction Model for 90-Day Mortality After Lung Resection Thu, 07 May 2026 00:00:00 -0700 ASO Author Reflections: Exosomal miR-423-5p Radiosensitizes Esophageal Cancer by Targeting MAP7D1 Wed, 06 May 2026 00:00:00 -0700 How to Find the Nerve: Nipple Nerve Allograft Reconstruction for Sensory Restoration in Nipple-Sparing Mastectomy Wed, 06 May 2026 00:00:00 -0700 ASO Author Reflections: It’s Not “Just” a Distal Pancreatectomy: The Impact of Postoperative Complications on Adjuvant Therapy Delivery in Left-Side Pancreatic Cancer Wed, 06 May 2026 00:00:00 -0700 ASO Author Reflections: From Blood Pressure Control to Tumor Risk: Genetic Clues Linking Antihypertensive Drug Targets to Urological Tumors Wed, 06 May 2026 00:00:00 -0700 The Full Scope: Standardization of the Use of Endoscopy for Earlier Diagnosis of Stomach Cancer in the USA Wed, 06 May 2026 00:00:00 -0700 Response to Letter to the Editor: Comments on “Surgery for Retroperitoneal Soft Tissue is Safe following Multimodal Treatment with Regional Hyperthermia” Tue, 05 May 2026 00:00:00 -0700 Step-by-Step Hepatic Artery and Celiac Axis Dissection According to the Inoue Classification During Robotic Pancreaticoduodenectomy Tue, 05 May 2026 00:00:00 -0700 Well-Differentiated Liposarcoma of the Psoas Muscle: A Distinct Anatomic Subset with Highly Favorable Outcomes Tue, 05 May 2026 00:00:00 -0700 Intracholecystic Papillary Neoplasms (ICPNs): Systematic Review and Meta-analysis of Epidemiological, Diagnostic, Immunohistochemical, and Clinical Features Tue, 05 May 2026 00:00:00 -0700 Correction: Secondary and Tertiary Cytoreduction for Colorectal Peritoneal Metastasis-Evaluate and Select Carefully, but Do Not Dismiss Mon, 04 May 2026 00:00:00 -0700 Correction: Risk Stratification of Postoperative Recurrence After Adjuvant Nivolumab for Resected Locally Advanced Esophageal Cancer: A Real-World Study Mon, 04 May 2026 00:00:00 -0700 ASO Visual Abstract: Protective Effect of Diuresis During Hyperthermia on Acute Kidney Injury in Cytoreductive Surgery with HIPEC Mon, 04 May 2026 00:00:00 -0700 ASO Author Reflections: Neoadjuvant Therapy as a Selection Strategy for Curative Resection in High-Risk Intrahepatic Cholangiocarcinoma Mon, 04 May 2026 00:00:00 -0700 ASO Author Reflections: Socioeconomic Disparities in Breast Tumors Persist Despite Universal Healthcare Mon, 04 May 2026 00:00:00 -0700 ASO Visual Abstract: Consensus Guidelines on Perioperative Care in Primary Retroperitoneal Sarcoma Surgery Mon, 04 May 2026 00:00:00 -0700 Neoadjuvant Therapy as a Selection Strategy for Curative Resection in High-Risk Intrahepatic Cholangiocarcinoma Mon, 04 May 2026 00:00:00 -0700 Predictive Value of Routine Imaging for the Diagnosis of Pathologic Complete Response After Neoadjuvant Chemotherapy in Breast Cancer Mon, 04 May 2026 00:00:00 -0700 ASO Visual Abstract: Immediate Second Look After Cytoreduction for Colorectal or Ovarian Carcinomatosis: An Invisible Gorilla Effect? Sat, 02 May 2026 00:00:00 -0700 ASO Author Reflections: sCD40 as a Preoperative Predictor in Pancreatic Cancer Surgery Sat, 02 May 2026 00:00:00 -0700 Leading Consortiums from the Ground Up: Leveraging Trainee Collaboration to Create Consensus Guidelines Sat, 02 May 2026 00:00:00 -0700 Do Postoperative Complications Impact Adjuvant Chemotherapy in Patients Undergoing Left-Side Pancreatectomy for Pancreatic Cancer? Sat, 02 May 2026 00:00:00 -0700 Combined Preoperative Risk Score Including sCD40, Leukocytes, and BMI Predicts Pancreas-Specific Complications After Pancreatic Cancer Surgery Sat, 02 May 2026 00:00:00 -0700 ASO Visual Abstract: The Margin of the Largest Tumor Predicts Overall Survival After Resection of Multi-tumor Colorectal Liver Metastases Thu, 30 Apr 2026 00:00:00 -0700 ASO Visual Abstract: Pancreatoduodenectomy or Pancreaticoduodenectomy? A Century of Evolving Terminology in Pancreatic Surgery Thu, 30 Apr 2026 00:00:00 -0700 ASO Visual Abstract: A Retrospective Examination of Neoadjuvant Chemotherapy for Metachronous Colorectal Peritoneal Metastases Prior to CRS/HIPEC Thu, 30 Apr 2026 00:00:00 -0700 ASO Visual Abstract: Combined Preoperative Risk Score Including sCD40, Leukocytes, and BMI Predicts Pancreas-Specific Complications After Pancreatic Cancer Surgery Thu, 30 Apr 2026 00:00:00 -0700 Laparoscopic Localization and Enucleation of Multiple Insulinomas Using a Combination of Indocyanine Green Fluorescence Imaging and Intraoperative Ultrasound Thu, 30 Apr 2026 00:00:00 -0700 ASO Author Reflections: Centralizing Esophagogastric Cancer Surgery: Beyond Volume Thresholds Thu, 30 Apr 2026 00:00:00 -0700 Predictors of Satisfaction with Breasts and Psychosocial Well-Being After Nipple-Sparing Mastectomy Thu, 30 Apr 2026 00:00:00 -0700 Neuron-Associated Transcriptional Enrichment Is Associated with Distinct Biological States and Predicts Poor Prognosis in Gastric Cancer Thu, 30 Apr 2026 00:00:00 -0700 Defining Recovery After Gastrectomy: Insights from Longitudinally Collected Patient-Reported Outcomes Thu, 30 Apr 2026 00:00:00 -0700 ASO Author Reflections: Tipping Points in Rectal Cancer Organ Preservation: A Markov Model Analysis Tue, 28 Apr 2026 00:00:00 -0700 ASO Visual Abstract: The Prognostic Rsole of Postoperative Inflammation after Minimally Invasive Resection for Colorectal Cancer Tue, 28 Apr 2026 00:00:00 -0700 ASO Visual Abstract: Predictive Value of Routine Imaging for the Diagnosis of Pathological Complete Response After Neoadjuvant Chemotherapy in Breast Cancer Tue, 28 Apr 2026 00:00:00 -0700 ASO Visual Abstract: Ki67 Gene Expression is Associated with Immune Cell Infiltration and Neoadjuvant Chemotherapy Response in ER+/HER2− Breast Cancer Tue, 28 Apr 2026 00:00:00 -0700 ASO Visual Abstract: Eligibility for Liver Transplantation in Patients with Intrahepatic Cholangiocarcinoma Tue, 28 Apr 2026 00:00:00 -0700 ASO Author Reflections: Rethinking Lymphedema Prophylaxis After Groin Dissection for Melanoma Tue, 28 Apr 2026 00:00:00 -0700 ASO Visual Abstract: The Impact of Postoperative Complications After Colon Cancer Surgery on Locoregional Recurrence: A Population-Based Dutch Cohort Study Tue, 28 Apr 2026 00:00:00 -0700 Mapping the Evidence for Surgical Care of Gastro-Entero-Pancreatic Neuroendocrine Tumors (GEP-NETs): A Scoping Review Tue, 28 Apr 2026 00:00:00 -0700 Reply to: “Methodological Considerations on Prognostic Modeling in Esophageal Cancer—Commentary on Liu et al. (2026)” Mon, 27 Apr 2026 00:00:00 -0700 ASO Author Reflections: Redefining Parenchyma-Preserving Surgery in Advanced Hilar Cholangiocarcinoma: The Robotic Perspective Mon, 27 Apr 2026 00:00:00 -0700 ASO Visual Abstract: Decision Modeling to Guide Management of Pancreatic IPMNs: Immediate Surgery or Initial Surveillance? Mon, 27 Apr 2026 00:00:00 -0700 ASO Visual Abstract: The Impact of Hospital Volume on Postoperative Outcomes for Esophagectomy and Gastrectomy: A Systematic Review and Meta-Analysis Mon, 27 Apr 2026 00:00:00 -0700 ASO Visual Abstract: Robotic Caval Replacement for Leiomyosarcoma of the Inferior Vena Cava Mon, 27 Apr 2026 00:00:00 -0700 |
||
|
| |||
|
Stable Supportive Footwear for Self-managing Hip Osteoarthritis Pain
Annals of Internal Medicine, Volume 179, Issue 4, Page 469-477, April 2026. <br/> Tue, 24 Feb 2026 08:00:00 +0000 Neither Metformin nor Ursodeoxycholic Acid Effectively Treats Postacute Sequelae of COVID-19 Annals of Internal Medicine, Volume 179, Issue 4, Page 478-485, April 2026. <br/> Tue, 24 Feb 2026 08:00:00 +0000 Outcomes of Density-Targeted Supplemental Breast Magnetic Resonance Imaging Screening by Breast Cancer Risk: Long-Term Health and Economic Considerations Annals of Internal Medicine, Volume 179, Issue 4, Page 486-496, April 2026. <br/> Tue, 24 Feb 2026 08:00:00 +0000 Optimizing Cervical Cancer Screening by Age at Vaccination for Human Papillomavirus: Health and Resource Implications Annals of Internal Medicine, Volume 179, Issue 4, Page 497-505, April 2026. <br/> Tue, 24 Feb 2026 08:00:00 +0000 Hemoglobin Concentration in Early Pregnancy and Severe Neonatal Morbidity and Mortality Annals of Internal Medicine, Volume 179, Issue 4, Page 506-514, April 2026. <br/> Tue, 24 Feb 2026 08:00:00 +0000 The Risk for Bleeding in Patients With Atrial Fibrillation From Concomitant Use of Apixaban or Rivaroxaban With Diltiazem Compared With Metoprolol Annals of Internal Medicine, Volume 179, Issue 4, Page 515-523, April 2026. <br/> Tue, 24 Feb 2026 08:00:00 +0000 Outpatient Treatment of Confirmed COVID-19: A Living, Rapid Review for the American College of Physicians (Version 3) Annals of Internal Medicine, Volume 179, Issue 4, Page 524-534, April 2026. <br/> Tue, 24 Feb 2026 08:00:00 +0000 Care of Bereaved Persons Annals of Internal Medicine, Volume 179, Issue 4, Page 535-547, April 2026. <br/> Tue, 24 Feb 2026 08:00:00 +0000 QUADAS-3: A Revised Tool for the Quality Assessment of Diagnostic Test Accuracy Studies Annals of Internal Medicine, Volume 179, Issue 4, Page 548-555, April 2026. <br/> Tue, 24 Feb 2026 08:00:00 +0000 QUADAS-3 Explanation and Elaboration: Guidance for Quality Assessment of Diagnostic Test Accuracy Studies Annals of Internal Medicine, Volume 179, Issue 4, April 2026. <br/> Tue, 24 Feb 2026 08:00:00 +0000 Outpatient Treatment of Confirmed COVID-19 in Symptomatic Adults: Living, Rapid Practice Points From the American College of Physicians (Version 3) Annals of Internal Medicine, Volume 179, Issue 4, Page 559-563, April 2026. <br/> Tue, 24 Feb 2026 08:00:00 +0000 A Synopsis of the 2025 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline for the Primary Care Management of Asthma Annals of Internal Medicine, Volume 179, Issue 4, Page 564-573, April 2026. <br/> Tue, 24 Feb 2026 08:00:00 +0000 How Would You Manage This Patient With Frequent Migraine Headaches? Grand Rounds Discussion From Beth Israel Deaconess Medical Center Annals of Internal Medicine, Volume 179, Issue 4, Page 574-585, April 2026. <br/> Tue, 24 Feb 2026 08:00:00 +0000 Physicians Are Not Providers: The Ethical Significance of Names in Health Care: A Policy Paper From the American College of Physicians Annals of Internal Medicine, Volume 179, Issue 4, Page 556-558, April 2026. <br/> Tue, 24 Feb 2026 08:00:00 +0000 New GRADE Evidence-to-Decision Framework for Pairwise and Multiple Comparisons (GRADE Guidance 45) Annals of Internal Medicine, Volume 179, Issue 4, Page 586-595, April 2026. <br/> Tue, 24 Feb 2026 08:00:00 +0000 The Case Against Six-Month Limits on Buprenorphine Telehealth Prescribing Annals of Internal Medicine, Volume 179, Issue 4, Page 596-597, April 2026. <br/> Tue, 24 Feb 2026 08:00:00 +0000 Dietary Guidelines: Tilting From Treatment Toward Prevention Annals of Internal Medicine, Volume 179, Issue 4, Page 598-599, April 2026. <br/> Tue, 24 Feb 2026 08:00:00 +0000 Use of Large-Language Models for Therapy: Promise and Perils Annals of Internal Medicine, Volume 179, Issue 4, Page 600-601, April 2026. <br/> Tue, 24 Feb 2026 08:00:00 +0000 Advancing Clinical Mastery: An Essential Element of Primary Care Revitalization Annals of Internal Medicine, Volume 179, Issue 4, Page 602-603, April 2026. <br/> Tue, 24 Feb 2026 08:00:00 +0000 Supplemental Magnetic Resonance Imaging in Breast Cancer Screening: The Challenge of Using Wisely Annals of Internal Medicine, Volume 179, Issue 4, Page 604-605, April 2026. <br/> Tue, 24 Feb 2026 08:00:00 +0000 Adapting Cervical Cancer Screening in Vaccinated Populations: Individualized Versus Population-Based Approaches Annals of Internal Medicine, Volume 179, Issue 4, Page 606-607, April 2026. <br/> Tue, 24 Feb 2026 08:00:00 +0000 Small Acts of Compassion: What Current Evidence Does Not Measure Annals of Internal Medicine, Volume 179, Issue 4, Page 608-609, April 2026. <br/> Tue, 24 Feb 2026 08:00:00 +0000 A New Approach to Reliever Therapy in Asthma: Implications of the U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline Annals of Internal Medicine, Volume 179, Issue 4, Page 610-611, April 2026. <br/> Tue, 24 Feb 2026 08:00:00 +0000 Suffering and Redemption Annals of Internal Medicine, Volume 179, Issue 4, Page 612, April 2026. <br/> Tue, 24 Feb 2026 08:00:00 +0000 Telehealth Utilization and Health Conditions Addressed Among the U.S. Medicare Population Annals of Internal Medicine, Volume 179, Issue 4, Page 614-617, April 2026. <br/> Tue, 24 Feb 2026 08:00:00 +0000 Death at Home or Hospice Among Physicians Annals of Internal Medicine, Volume 179, Issue 4, Page 617-619, April 2026. <br/> Tue, 24 Feb 2026 08:00:00 +0000 |
ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide November 20, 2025 SITC 2025: Macrophage-targeting CAR monocytes Improve Immunotherapy Outcomes in Breast Cancer SITC 2025: Results from the Phase 1 / 2a AERIAL Trial Evaluating Lateral CAR-T LEU011 for the Treatment of Solid Tumors SITC 2025: Data Shows Promising Preclinical Results for SynKIR™-110 in Solid Tumors SITC 2025: Long-term Complete Responses of T-Cell Therapies for HPV-Related Cancers ESMO 2025: A ctDNA-guided Approach to Helps Personalize Adjuvant Chemotherapy Colon Cancer October 20, 2025 ESMO 2025: Circulating Tumor DNA (ctDNA)–guided Treatment in Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer October 20, 2025 ESMO 2025: Vimseltinib Demonstrates Statistically Significant and Clinically Meaningful Benefit in Patients Diagnosed with Tenosynovial Giant Cell Tumor October 20, 2025 ESMO 2025: Belzutifan Shrinks Rare Neuroendocrine Tumors and Improves Patients Symptoms October 20, 2025 ESMO 2025: Previously Treated Advanced Kidney Cancer Patients may Benefit from Targeted Therapies October 19, 2025 ESMO 2025: Higher Thymic Health Linked to Better Patients’ Response to Immunotherapy October 19, 2025 ESMO 2025: A New Generation of Antibody-drug Conjugates Demonstrates Unprecedented Promise in Early-Stage Breast Cancer October 19, 2025 ESMO 2025: First In Human Dose Escalation for TT125-802 Shows Durable Confirmed Responses in Non-small Cell Lung Cancer October 18, 2025 ESMO 2025: Zongertinib Shows a 77% ORR in Treatment-naïve Patients with Advanced HER2 Mutant NSCLC October 18, 2025 ESMO 2025: First Phase 1 Safety and Efficacy Data Presented of Izalontamab Brengitecan in Patients with Advanced Solid Tumors October 18, 2025 ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide November 20, 2025 Study Shows Intranasal Vaccine Offers Promise as a Non-invasive Therapeutic Option for Treatment of Cervical Cancer November 19, 2025 Cancer Cells Use the ‘Adaptive Processes’ to Initiate Resistance and Survive Treatment November 19, 2025 FDA’s Plan To Boost Biosimilar Drugs Could Stall at the Patent Office November 17, 2025 Agency, Adaptation, and Access: Hospitals Leveraging Locum Tenens to Bridge the Physician Gap November 14, 2025 ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide November 20, 2025 Study Shows Intranasal Vaccine Offers Promise as a Non-invasive Therapeutic Option for Treatment of Cervical Cancer November 19, 2025 Cancer Cells Use the ‘Adaptive Processes’ to Initiate Resistance and Survive Treatment November 19, 2025 Daiichi Sankyo Out-Licenses Investigational Agent DS-6051 to AnHeart Therapeutics December 19, 2018 How Meaningful Will Changes Be to Ethical Guidelines Following Jose Baselga’s Fall? October 9, 2018 Reversal of Fortune: How a Vilified Drug Became a Life-saving Agent in the ‘War’ Against Cancer November 30, 2013 |
ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide
November 20, 2025 Pediatric Oncology: Novel Treatment Proves ‘Miracle’ for 6-Year-Old with Leukemia Jiahui International Cancer Center Successfully Treats a 78-year-old Patient from New Zealand with Advanced CAR T-Cell Therapy SITC 2025: Data Shows Promising Preclinical Results for SynKIR™-110 in Solid Tumors Combination Treatment of Ianalumab + Ibrutinib May Help Some Patients to Discontinue Daily Therapy Liposomal Spherical Nucleic Acids Constructs Impact both Chemotherapeutic Delivery and Cell Targeting November 1, 2025 Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma Shows Positive Topline Results October 24, 2025 Study Identifies TRβ as a Targetable Driver in the Growth of Prostate Cancer October 21, 2025 ESMO 2025: A ctDNA-guided Approach to Helps Personalize Adjuvant Chemotherapy Colon Cancer October 20, 2025 ESMO 2025: Circulating Tumor DNA (ctDNA)–guided Treatment in Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer October 20, 2025 ESMO 2025: Vimseltinib Demonstrates Statistically Significant and Clinically Meaningful Benefit in Patients Diagnosed with Tenosynovial Giant Cell Tumor October 20, 2025 ESMO 2025: Belzutifan Shrinks Rare Neuroendocrine Tumors and Improves Patients Symptoms October 20, 2025 ESMO 2025: Previously Treated Advanced Kidney Cancer Patients may Benefit from Targeted Therapies October 19, 2025 ESMO 2025: A New Generation of Antibody-drug Conjugates Demonstrates Unprecedented Promise in Early-Stage Breast Cancer October 19, 2025 ESMO 2025: First In Human Dose Escalation for TT125-802 Shows Durable Confirmed Responses in Non-small Cell Lung Cancer October 18, 2025 ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide November 20, 2025 Study Shows Intranasal Vaccine Offers Promise as a Non-invasive Therapeutic Option for Treatment of Cervical Cancer November 19, 2025 Cancer Cells Use the ‘Adaptive Processes’ to Initiate Resistance and Survive Treatment November 19, 2025 FDA’s Plan To Boost Biosimilar Drugs Could Stall at the Patent Office November 17, 2025 Agency, Adaptation, and Access: Hospitals Leveraging Locum Tenens to Bridge the Physician Gap November 14, 2025 ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide November 20, 2025 Study Shows Intranasal Vaccine Offers Promise as a Non-invasive Therapeutic Option for Treatment of Cervical Cancer November 19, 2025 Cancer Cells Use the ‘Adaptive Processes’ to Initiate Resistance and Survive Treatment November 19, 2025 Daiichi Sankyo Out-Licenses Investigational Agent DS-6051 to AnHeart Therapeutics December 19, 2018 How Meaningful Will Changes Be to Ethical Guidelines Following Jose Baselga’s Fall? October 9, 2018 Reversal of Fortune: How a Vilified Drug Became a Life-saving Agent in the ‘War’ Against Cancer November 30, 2013 |
|
|
| |||
|
Entrada crashes as Duchenne therapy comes in ‘below expectations’ in early study
Entrada Therapeutics saw a 2.36% dystrophin increase in patients treated with its oligonucleotide asset—a number that fell short of the company’s prior guidance of a double-digit improvement.
CellCentric secures $220M in Europe’s biggest private biotech fundraise of 2026 Pfizer-backed cancer company CellCentric will use the cash to support the launch of a pivotal myeloma trial testing its potentially first-in-class oral treatment this year.
J&J pushes dual-antibody IBD therapy into Phase 3 despite mid-stage fails Johnson & Johnson plans to advance the co-antibody therapy, which combines its IL-23 blocker Tremfya and the TNF-alpha inhibitor Simponi, into late-stage testing for Crohn’s disease and ulcerative colitis.
Corcept ties ALS drug to improved 2-year survival as Phase 3 start date nears Corcept Therapeutics’ amyotrophic lateral sclerosis drug was linked to an 87% reduction in the risk of death, a result the biotech hopes to replicate in an upcoming Phase 3 trial.
Novartis, PTC push Huntington’s drug into Phase 3, mum on accelerated approval Phase 2 data from PTC Therapeutics showed that the Novartis-partnered Huntington’s disease asset slowed progression by more than 50%. Analysts say the decision to initiate a last-stage trial reflects a lack of confidence in an accelerated FDA nod.
Compass shares crash as ‘confounding’ survival data raise approvability questions for bispecific While tovecimig met the main goal of progression-free survival in a Phase 2/3 trial, it did not improve overall survival.
Tortugas takes neuro deep dive with $106M to develop Eisai, Hansoh programs With programs from Eisai and Hansoh Pharmaceutical in hand, Tortugas Neuroscience has emerged with hopes of delivering daily oral treatments to patients with central nervous system conditions.
Agenus cancer cocktail records 0% response rate, missing midstage goal An investigational cocktail was tied to a 0% overall response rate in patients with gastroesophageal cancer, but developers Agenus and MiNK Therapeutics aren’t giving up on the program just yet.
Merck’s early PD-1/VEGF data competitive in lung cancer, but Summit ‘looms large’ While Merck’s PD-1/VEGF asset appears to match the performance of Summit Therapeutics’ ivonescimab, the pharma’s Phase 1/2 readout in non-small cell lung cancer still leaves analysts with some questions moving into later-stage development.
Allogene stock sails after CAR T clears residual lymphoma in early data cut Pivotal findings for the off-the-shelf cell therapy surpassed William Blair’s expectations and sent Allogene Therapeutics’ stock up more than 50% in pre-market trading Monday morning.
Actio Biosciences Announces Initiation of KYRON Phase 1b/2 Trial of ABS-1230 for the Treatment of KCNT1-Related Epilepsy and Acceptance into FDA’s Rare Disease Evidence Principles Process ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update InnoCare Announces Approval of a Phase II Clinical Trial of TYK2 Inhibitor ICP-488 for Sjögren’s Syndrome in China Vaxart Provides Business Update and Reports First Quarter 2026 Financial Results Beacon Therapeutics Announces Positive 12-Month Safety and Efficacy Update from Phase 2 DAWN Trial of laru-zova in Patients with X-linked Retinitis Pigmentosa (XLRP) at ARVO 2026 Annual Meeting BioRestorative Therapies Reports Expanded Phase 2 Blinded Dataset for BRTX-100 Showing Sustained Pain and Functional Improvements in Chronic Lumbar Disc Disease Ukko Announces First Participant Dosed in Phase 1/2a Clinical Study Evaluating UKK-0018 for Peanut Allergy Treatment enGene Announces Updated Interim Results From LEGEND Pivotal Cohort Cadrenal Therapeutics Reports First Quarter 2026 Financial Results and Provides Phase 3 Development Update on CAD-1005 Following End-of-Phase 2 Meeting with FDA AIM ImmunoTech Announces 50% Objective Response Rate (ORR) in UPMC Recurrent Ovarian Cancer Phase 2 Clinical Trial, Suggesting Breakthrough Combination Potential Cardiol Therapeutics’ Phase II MAvERIC Results Accepted for Publication in the Journal of the American Heart Association Opus Genetics Completes Enrollment in Cohort 1 of Phase 1/2 OPGx-BEST1 Gene Therapy Study Entrada Therapeutics Announces Positive Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study PHERGain and PHERGain-2 advance therapeutic de-escalation in early HER2-positive breast cancer in selected patients Mirum Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update Revolution Medicines Announces Publication in New England Journal of Medicine of Phase 1/2 Clinical Data on Daraxonrasib in Pancreatic Cancer Entrada Therapeutics to Announce Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study on May 7, 2026 Bioxodes presents positive final Phase 2a intracerebral hemorrhage results at ESOC affirming breakthrough potential of BIOX-101 Aptevo Reports 87% Clinical Benefit and 81% Remission in 31 Evaluable Frontline AML Patients Through Cohort 5, Substantially Outperforming Benchmark; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update |
CellCentric secures $220M in Europe’s biggest private biotech fundraise of 2026
Pfizer-backed cancer company CellCentric will use the cash to support the launch of a pivotal myeloma trial testing its potentially first-in-class oral treatment this year.
Viridian turns green again as new Phase 3 data vindicate thyroid eye disease drug Viridian Therapeutics’ elegrobart normalized the degree of eye protrusion and improved double vision in a Phase 3 study. The company plans to file for approval in the first quarter of 2027.
Summit shares descend as PD-1/VEGF asset misses early survival mark Summit Therapeutics planned an early interim progression-free survival readout for HARMONi-3 in the hope of enabling earlier regulatory engagement—but the early analysis delivered disappointment for the company and shareholders.
Compass shares crash as ‘confounding’ survival data raise approvability questions for bispecific While tovecimig met the main goal of progression-free survival in a Phase 2/3 trial, it did not improve overall survival.
Intellia heads to FDA after notching first late-stage win for in vivo gene editor With Phase 3 data in hand, Intellia Therapeutics is seeking approval for its in vivo CRISPR gene editing therapy for hereditary angioedema.
Merck, Eisai’s Keytruda triplet fails to improve survival in kidney cancer A triplet regimen comprising Merck’s Welireg and PD-1 blockbuster Keytruda and Eisai’s Lenvima flopped in a Phase 3 renal cell carcinoma trial.
Gilead, Arcus tumble again in TIGIT, triggering 2 trial culls The Phase 3 failure has prompted Gilead Sciences and Arcus Biosciences to terminate a mid-stage study of their TIGIT asset in lung cancer.
Novo’s late-stage sickle cell win piles pressure on competitors Novo Nordisk’s etavopivat elicited a 27% drop in vaso-occlusive crises and 48.7% hemoglobin response after 24 weeks, creating “separation amongst PK class candidates,” Truist analysts said on Monday. Novo plans to seek FDA approval in the back half of 2026.
Revolution rises 40% as pancreatic cancer drug doubles survival In a difficult disease, Revolution Medicines achieved what the pancreatic cancer community has long desired: a significant improvement in survival. The Phase 3 results will support global regulatory filings.
IDEAYA and Servier’s eye cancer drug heads to FDA after delivering ‘best in class’ efficacy Darovasertib, in combination with crizotinib, more than doubled progression-free survival in a registrational trial, leading Truist analysts to declare a “best-in-class efficacy profile” for the PKC inhibitor.
Day One and Servier Complete Enrollment in Pivotal Phase 3 FIREFLY-2 Trial of Tovorafenib as a Front-Line Treatment for Pediatric Low-Grade Glioma (pLGG) Vistagen Announces Completion of Last Patient Visit in PALISADE-4 Phase 3 Public Speaking Challenge Study of Fasedienol for Acute Treatment of Social Anxiety Disorder Artiva Announces Positive Initial Clinical Data with AlloNK® Across Multiple Autoimmune Diseases and FDA Alignment to Initiate Phase 3 Registrational Trial in Rheumatoid Arthritis in 2026 Chance Pharma Announces NMPA Acceptance of New Drug Application for Investigational Respiratory Drug CXG87 Kodiak Sciences Announces Recent Business Highlights and First Quarter 2026 Financial Results Incyte Announces 24-Week Long-Term Data from Phase 3 TRuE-AD4 Trial of Opzelura® (ruxolitinib) Cream in Adults with Moderate Atopic Dermatitis Cadrenal Therapeutics Reports First Quarter 2026 Financial Results and Provides Phase 3 Development Update on CAD-1005 Following End-of-Phase 2 Meeting with FDA Solid Biosciences Doses First Participant in Phase 3 IMPACT DUCHENNE Clinical Trial Evaluating SGT-003 in Duchenne Muscular Dystrophy BriaCell Adds NYU Langone Health’s Perlmutter Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter 2026 Financial Results Investigational PET Tracer Iodine 124 Evuzamitide from Bayer Met Primary Endpoints in Phase III Study in Patients Suspected to Have Cardiac Amyloidosis Moderna Announces New England Journal of Medicine Publication of Pivotal Phase 3 Clinical Safety and Efficacy Data for Its Investigational Seasonal Influenza Vaccine, mRNA-1010 19.3% Weight Reduction, 16.5 cm Waist Circumference Decrease, SBP/DBP Reductions of 22.9/12.9 mmHg, 70.7 μmol/L Uric Acid Reduction, and 33.6% Triglyceride Reduction: BGM0504 Demonstrates Comprehensive Cardiometabolic Regulation Capabilities Alebund Pharmaceuticals Announces Completion of Patient Enrollment in Global Phase III Pivotal Multi-Regional Clinical Trial of AP301 for Hyperphosphatemia Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 2026 Financial Results Sebela Pharmaceuticals Presents Phase 3 Tegoprazan Data in Erosive Esophagitis at Digestive Disease Week® (DDW) 2026 Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑2 Clinical Trial in Chronic Thyroid Eye Disease Johnson & Johnson study shows TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to demonstrate efficacy in perianal fistulizing Crohn’s disease BGM0504 Achieves 19.3% Robust Weight Reduction, 16.5 cm Waist Circumference Decrease, Significant SBP/DBP Improvements of 22.9/12.9 mmHg, and 70.7 μmol/L Uric Acid Reduction; Phase III Trial Meets Primary Endpoint and All Key Secondary Endpoints IMUNON to Hold First Quarter 2026 Financial Results and Business Update Conference Call on Tuesday, May 12, 2026 |
Entrada crashes as Duchenne therapy comes in ‘below expectations’ in early study
Entrada Therapeutics saw a 2.36% dystrophin increase in patients treated with its oligonucleotide asset—a number that fell short of the company’s prior guidance of a double-digit improvement.
Fibrosis, IPF and the search for better therapies In this episode of Denatured, you’ll be hearing from Georg Vo Beiske, CEO of Tribune Therapeutics and Jonas Hallén, co-founder and Chief Medical Officer of Calluna Pharma. We dive into IPF and fibrosis challenges, unpacking treatment hurdles, emerging targets, unmet needs and expansion paths beyond the lung.
CellCentric secures $220M in Europe’s biggest private biotech fundraise of 2026 Pfizer-backed cancer company CellCentric will use the cash to support the launch of a pivotal myeloma trial testing its potentially first-in-class oral treatment this year.
Viridian turns green again as new Phase 3 data vindicate thyroid eye disease drug Viridian Therapeutics’ elegrobart normalized the degree of eye protrusion and improved double vision in a Phase 3 study. The company plans to file for approval in the first quarter of 2027.
J&J pushes dual-antibody IBD therapy into Phase 3 despite mid-stage fails Johnson & Johnson plans to advance the co-antibody therapy, which combines its IL-23 blocker Tremfya and the TNF-alpha inhibitor Simponi, into late-stage testing for Crohn’s disease and ulcerative colitis.
Foundayo’s liver failure blip weighs down Lilly shares but analysts unconcerned The selloff in Eli Lilly’s shares was “overdone,” according to RBC Capital Markets, which noted that the overall safety profile of Foundayo remains favorable.
IPF draws investor heat as biotechs target fibrosis halt, better tolerability Novel targets aim to stop lung scarring—where current drugs only slow it—while improving tolerability and unlocking fibrosis in other organs next
Gene therapy’s evidence problem—lessons from recent FDA decisions Comprehending the spate of recent rejections in the cell and gene therapy space may require looking no further than early-stage clinical trials of candidates from REGENXBIO, Excision BioTherapeutics and Intellia Therapeutics.
Summit shares descend as PD-1/VEGF asset misses early survival mark Summit Therapeutics planned an early interim progression-free survival readout for HARMONi-3 in the hope of enabling earlier regulatory engagement—but the early analysis delivered disappointment for the company and shareholders.
Corcept ties ALS drug to improved 2-year survival as Phase 3 start date nears Corcept Therapeutics’ amyotrophic lateral sclerosis drug was linked to an 87% reduction in the risk of death, a result the biotech hopes to replicate in an upcoming Phase 3 trial.
Actio Biosciences Announces Initiation of KYRON Phase 1b/2 Trial of ABS-1230 for the Treatment of KCNT1-Related Epilepsy and Acceptance into FDA’s Rare Disease Evidence Principles Process Alpha Tau Completes Patient Enrollment in its U.S. Pivotal Skin Cancer Study, Advancing Towards Goal of FDA Approval of Alpha DaRT® to Treat Recurrent Cutaneous Squamous Cell Carcinoma Day One and Servier Complete Enrollment in Pivotal Phase 3 FIREFLY-2 Trial of Tovorafenib as a Front-Line Treatment for Pediatric Low-Grade Glioma (pLGG) ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update Vistagen Announces Completion of Last Patient Visit in PALISADE-4 Phase 3 Public Speaking Challenge Study of Fasedienol for Acute Treatment of Social Anxiety Disorder Artiva Announces Positive Initial Clinical Data with AlloNK® Across Multiple Autoimmune Diseases and FDA Alignment to Initiate Phase 3 Registrational Trial in Rheumatoid Arthritis in 2026 Chance Pharma Announces NMPA Acceptance of New Drug Application for Investigational Respiratory Drug CXG87 InnoCare Announces Approval of a Phase II Clinical Trial of TYK2 Inhibitor ICP-488 for Sjögren’s Syndrome in China Kodiak Sciences Announces Recent Business Highlights and First Quarter 2026 Financial Results Vaxart Provides Business Update and Reports First Quarter 2026 Financial Results Beacon Therapeutics Announces Positive 12-Month Safety and Efficacy Update from Phase 2 DAWN Trial of laru-zova in Patients with X-linked Retinitis Pigmentosa (XLRP) at ARVO 2026 Annual Meeting BioRestorative Therapies Reports Expanded Phase 2 Blinded Dataset for BRTX-100 Showing Sustained Pain and Functional Improvements in Chronic Lumbar Disc Disease Incyte Announces 24-Week Long-Term Data from Phase 3 TRuE-AD4 Trial of Opzelura® (ruxolitinib) Cream in Adults with Moderate Atopic Dermatitis Ukko Announces First Participant Dosed in Phase 1/2a Clinical Study Evaluating UKK-0018 for Peanut Allergy Treatment enGene Announces Updated Interim Results From LEGEND Pivotal Cohort Alpha Tau Successfully Treats First Pancreatic Cancer Patient in Italy with Alpha DaRT® at the University of Verona’s Pancreas Institute Cadrenal Therapeutics Reports First Quarter 2026 Financial Results and Provides Phase 3 Development Update on CAD-1005 Following End-of-Phase 2 Meeting with FDA Quoin Pharmaceuticals Provides Corporate Update and Reports First Quarter 2026 Financial Results Solid Biosciences Doses First Participant in Phase 3 IMPACT DUCHENNE Clinical Trial Evaluating SGT-003 in Duchenne Muscular Dystrophy AIM ImmunoTech Announces 50% Objective Response Rate (ORR) in UPMC Recurrent Ovarian Cancer Phase 2 Clinical Trial, Suggesting Breakthrough Combination Potential |
|
|
| |||
|
FDA approves zenocutuzumab-zbco for advanced, unresectable or metastatic cholangiocarcinoma
On May 8, 2026, the Food and Drug Administration approved zenocutuzumab-zbco (Bizengri, Partner Therapeutics, Inc.) for adults with advanced, unresectable or metastatic cholangiocarcinoma harboring a neuregulin 1 (NRG1) gene fusion with disease progression on or after prior systemic therapy. NRG1-fusion positive cholangiocarcinoma is an extremely rare, life-threatening malignancy.
Fri, 08 May 2026 00:00:04 -0700
FDA approves vepdegestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer On May 1, 2026, the Food and Drug Administration approved vepdegestrant (Veppanu, Arvinas Operations, Inc.), a heterobifunctional protein degrader, for adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy.
Fri, 01 May 2026 00:00:04 -0700
FDA approves relacorilant with nab-paclitaxel for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer On March 25, 2026, the Food and Drug Administration approved relacorilant (Lifyorli, Corcept Therapeutics Inc.), a glucocorticoid receptor antagonist, in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab.
Wed, 25 Mar 2026 00:00:04 -0700
FDA approves nivolumab with chemotherapy for previously untreated Hodgkin lymphoma On March 20, 2026, the Food and Drug Administration approved nivolumab (Opdivo, Bristol Myers Squibb Company) with doxorubicin, vinblastine, and dacarbazine (AVD) for adult and pediatric patients 12 years and older with previously untreated, Stage III or IV classical Hodgkin lymphoma (cHL).
Fri, 20 Mar 2026 00:00:04 -0700
FDA approves teclistamab in combination with daratumumab hyaluronidase-fihj for relapsed or refractory multiple myeloma On March 5, 2026, the Food and Drug Administration approved teclistamab (Tecvayli, Janssen Biotech, Inc.) in combination with daratumumab hyaluronidase-fihj for adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent.
Thu, 05 Mar 2026 00:00:04 -0800
FDA grants accelerated approval to zongertinib for unresectable or metastatic non-squamous non-small cell lung cancer On February 26, 2026, the Food and Drug Administration granted accelerated approval to zongertinib (Hernexeos, Boehringer Ingelheim Pharmaceuticals, Inc.), a kinase inhibitor, for an expanded indication for adults with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations, as detected by an FDA-authorized test.
Thu, 26 Feb 2026 00:00:04 -0800
FDA grants traditional approval to encorafenib for metastatic colorectal cancer with a BRAF V600E mutation On February 24, 2026, the Food and Drug Administration granted traditional approval to encorafenib (Braftovi, Array BioPharma Inc., a subsidiary of Pfizer Inc.) in combination with cetuximab and fluorouracil-based chemotherapy for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, as detected by an FDA-authorized test. Encorafenib received accelerated approval in combination with cetuximab and mFOLFOX6 for metastatic colorectal cancer with BRAF V600E mutation in 2024.
Tue, 24 Feb 2026 00:00:04 -0800
FDA approves acalabrutinib with venetoclax for chronic lymphocytic leukemia or small lymphocytic lymphoma On February 19, 2026, the Food and Drug Administration approved acalabrutinib (Calquence, AstraZeneca) tablets and capsules in combination with venetoclax (Venclexta, AbbVie Inc. and Genentech Inc.) for adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Thu, 19 Feb 2026 00:00:04 -0800
FDA approves pembrolizumab with paclitaxel for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma On February 10, 2026, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) as well as pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck) in combination with paclitaxel, with or without bevacizumab, for adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma whose tumors express PD-L1 (CPS≥1) as determined by an FDA-authorized test, and who have received one or two prior systemic treatment regimens.
Tue, 10 Feb 2026 00:00:04 -0800
Safety labeling update for capecitabine and fluorouracil (5-FU) on risks associated with dihydropyrimidine dehydrogenase (DPD) deficiency Thu, 05 Feb 2026 00:00:04 -0800
FDA approves daratumumab and hyaluronidase-fihj with bortezomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma On January 27, 2026, the Food and Drug Administration approved daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen Biotech, Inc.) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for adults with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant (ASCT).
Tue, 27 Jan 2026 00:00:04 -0800
FDA approves amivantamab and hyaluronidase-lpuj for subcutaneous injection On December 17, 2025, the Food and Drug Administration approved amivantamab and hyaluronidase-lpuj (Rybrevant Faspro, Janssen Biotech, Inc.) for subcutaneous injection for adult patients across all indications approved for the intravenous formulation of amivantamab (Rybrevant, Janssen Biotech, Inc.). See the prescribing information for the specific indications.
Wed, 17 Dec 2025 00:00:04 -0800
FDA grants regular approval to rucaparib for metastatic castration-resistant prostate cancer On December 17, 2025, the Food and Drug Administration approved rucaparib (Rubraca, pharmaand GmbH) for adults with a deleterious BRCA mutation (BRCAm) (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) previously treated with an androgen receptor-directed therapy. Patients should be selected for therapy using an FDA-approved companion diagnostic (CDx).
Wed, 17 Dec 2025 00:00:04 -0800
FDA approves fam-trastuzumab deruxtecan-nxki with pertuzumab for unresectable or metastatic HER2-positive breast cancer On December 15, 2025, the Food and Drug Administration approved fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) in combination with pertuzumab for the first-line treatment of adults with unresectable or metastatic HER2-positive (IHC 3+ or ISH+) breast cancer as determined by an FDA-approved test.
Mon, 15 Dec 2025 00:00:04 -0800
FDA approves niraparib and abiraterone acetate plus prednisone for BRCA2-mutated metastatic castration-sensitive prostate cancer On December 12, 2025, the Food and Drug Administration approved niraparib and abiraterone acetate (Akeega, Janssen Biotech, Inc.) with prednisone for adults with deleterious or suspected deleterious BRCA2-mutated (BRCA2m) metastatic castration-sensitive prostate cancer (mCSPC), as determined by an FDA-approved test.
Fri, 12 Dec 2025 00:00:04 -0800
FDA approves lisocabtagene maraleucel for relapsed or refractory marginal zone lymphoma On December 4, 2025, the Food and Drug Administration approved lisocabtagene maraleucel (Breyanzi, Juno Therapeutics, Inc., a Bristol-Myers Squibb Company) for adults with relapsed or refractory marginal zone lymphoma (MZL) who have received at least two prior lines of systemic therapy
Thu, 04 Dec 2025 00:00:04 -0800
FDA grants traditional approval to pirtobrutinib for chronic lymphocytic leukemia and small lymphocytic lymphoma On December 3, 2025, the Food and Drug Administration granted traditional approval to pirtobrutinib (Jaypirca, Eli Lilly and Company) for adults with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have previously been treated with a covalent BTK inhibitor. In 2023, FDA granted accelerated approval to pirtobrutinib for adults with CLL/SLL who have received at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor.
Wed, 03 Dec 2025 00:00:04 -0800
FDA approves durvalumab for resectable gastric or gastroesophageal junction adenocarcinoma On November 25, 2025, the Food and Drug Administration approved durvalumab (Imfinzi, AstraZeneca) with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy as neoadjuvant and adjuvant treatment, followed by single agent durvalumab, for adults with resectable gastric or gastroesophageal junction adenocarcinoma (GC/GEJC).
Tue, 25 Nov 2025 00:00:04 -0800
FDA approves pembrolizumab with enfortumab vedotin-ejfv for muscle invasive bladder cancer On November 21, 2025, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck) with enfortumab vedotin-ejfv (Padcev, Astellas Pharma) as neoadjuvant treatment followed by adjuvant treatment after cystectomy for adults with muscle invasive bladder cancer (MIBC) who are ineligible for cisplatin.
Fri, 21 Nov 2025 00:00:04 -0800
FDA grants traditional approval to tarlatamab-dlle for extensive stage small cell lung cancer On November 19, 2025, the Food and Drug Administration granted traditional approval to tarlatamab-dlle (Imdelltra, Amgen Inc.) for adults with extensive stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy. Tarlatamab-dlle received accelerated approval for this indication in 2024.
Wed, 19 Nov 2025 00:00:04 -0800
FDA grants accelerated approval to sevabertinib for non-squamous non-small cell lung cancer On November 19, 2025, the Food and Drug Administration granted accelerated approval to sevabertinib (Hyrnuo, Bayer HealthCare Pharmaceuticals Inc.), a kinase inhibitor, for adults with locally advanced or metastatic, non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations, as detected by an FDA-approved test, and who have received a prior systemic therapy.
Wed, 19 Nov 2025 00:00:04 -0800
FDA grants traditional approval to daratumumab and hyaluronidase-fihj for newly diagnosed light chain amyloidosis On November 19, 2025, the Food and Drug Administration granted traditional approval to daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen Biotech Inc.) with bortezomib, cyclophosphamide, and dexamethasone (VCd) for newly diagnosed light chain (AL) amyloidosis. FDA granted accelerated approval for this indication in 2021.
Wed, 19 Nov 2025 00:00:04 -0800
FDA approves selumetinib for adults with neurofibromatosis type 1 with symptomatic, inoperable plexiform neurofibromas On November 19, 2025, the Food and Drug Administration approved selumetinib (KOSELUGO, AstraZeneca Pharmaceuticals LP) for adults with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN). FDA previously approved selumetinib capsules and granules for pediatric patients 1 year of age and older for this indication.
Wed, 19 Nov 2025 00:00:04 -0800
FDA approves epcoritamab-bysp for follicular lymphoma indications On November 18, 2025, the Food and Drug Administration approved epcoritamab-bysp (Epkinly, Genmab US, Inc.) with lenalidomide and rituximab for relapsed or refractory follicular lymphoma (FL). The FDA also granted traditional approval to epcoritamab-bysp as monotherapy for relapsed or refractory FL after two or more lines of systemic therapy (epcoritamab-bysp was granted accelerated approval for this indication in 2024).
Tue, 18 Nov 2025 00:00:04 -0800
|
Improving mitochondria and ER stability helps eliminate upper motor neuron degeneration that occurs due to mSOD1 toxicity and TDP-43 pathology.
Clin Transl Med. 2021 Feb;11(2):e336. doi: 10.1002/ctm2.336. Genç B, Gautam M, Gözütok Ö, Dervishi I, Sanchez S, Goshu GM, Koçak N, Xie E, Silverman RB, Özdinler PH Impact of high-power short-duration atrial fibrillation ablation technique on the incidence of silent cerebral embolism: a prospective randomized controlled study. BMC Med. 2023 Nov 23;21(1):461. doi: 10.1186/s12916-023-03180-3. Chen WJ, Gan CX, Cai YW, Liu YY, Xiao PL, Zou LL, Xiong QS, Qin F, Tao XX, Li R, Du HA, Liu ZZ, Yin YH, Ling ZY Tofersen for Amyotrophic Lateral Sclerosis: Genetic Treatment With Precision Medicine: The Future of ALS Treatment. J Clin Neuromuscul Dis. 2025 Mar 1;26(3):117-119. doi: 10.1097/CND.0000000000000517. Hamad AA Chest CT practice and protocols for COVID-19 from radiation dose management perspective. Eur Radiol. 2020 Dec;30(12):6554-6560. doi: 10.1007/s00330-020-07034-x. Epub 2020 Jul 3. Kalra MK, Homayounieh F, Arru C, Holmberg O, Vassileva J Molecular cloning, overexpression, and purification of a major xylanase from Aspergillus oryzae. Biosci Biotechnol Biochem. 2000 Dec;64(12):2734-8. doi: 10.1271/bbb.64.2734. Kimura T, Suzuki H, Furuhashi H, Aburatani T, Morimoto K, Karita S, Sakka K, Ohmiya K Modifiable risk factors and risk of schizophrenia and bipolar disorder across severities of genetic risk. J Affect Disord. 2026 Aug 15;407:121800. doi: 10.1016/j.jad.2026.121800. Epub 2026 Apr 13. Cui Y, Sun Y, Liu S, Song J, Wang X, Li N Comparative Effectiveness of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter 2 Inhibitors, Dipeptidyl Peptidase-4 Inhibitors, and Sulfonylureas for Sight-Threatening Diabetic Retinopathy. Ophthalmol Retina. 2024 Oct;8(10):943-952. doi: 10.1016/j.oret.2024.05.003. Epub 2024 May 11. Barkmeier AJ, Herrin J, Swarna KS, Deng Y, Polley EC, Umpierrez GE, Galindo RJ, Ross JS, Mickelson MM, McCoy RG Diagnostic accuracy of the Gold Coast Criteria for amyotrophic lateral sclerosis: a systematic review and meta-analysis. Clin Neurophysiol. 2025 Nov;179:2111005. doi: 10.1016/j.clinph.2025.2111005. Epub 2025 Sep 15. von Quednow E, Husain N, Łajczak P, Linha Secco G, Koppanatham A Tofersen: A Review in Amyotrophic Lateral Sclerosis Associated with SOD1 Mutations. CNS Drugs. 2025 Sep;39(9):903-912. doi: 10.1007/s40263-025-01204-5. Epub 2025 Jul 10. McGuigan A, Blair HA Tofersen for SOD1 amyotrophic lateral sclerosis: a systematic review and meta-analysis. Neurol Sci. 2025 May;46(5):1977-1985. doi: 10.1007/s10072-025-07994-2. Epub 2025 Jan 17. Hamad AA, Alkhawaldeh IM, Nashwan AJ, Meshref M, Imam Y Metformin for Clozapine Associated Obesity: A Systematic Review and Meta-Analysis. PLoS One. 2016 Jun 15;11(6):e0156208. doi: 10.1371/journal.pone.0156208. eCollection 2016. Siskind DJ, Leung J, Russell AW, Wysoczanski D, Kisely S SIRT3 deacetylates STEAP4 to modulate cuproptosis sensitivity via mitochondrial metabolic reprogramming in HBV-related HCC. Cell Death Differ. 2026 Mar 16. doi: 10.1038/s41418-026-01713-w. Du ZB, Wu XM, Lei JM, Cai YX, He J, Qian B, He XX, Han WH, Lu Y, Xia XG, Zheng HY, Guo DB, Yao YL, Li WG, Lin YC, Lin ZN Small babies, big risks: global estimates of prevalence and mortality for vulnerable newborns to accelerate change and improve counting. Lancet. 2023 May 20;401(10389):1707-1719. doi: 10.1016/S0140-6736(23)00522-6. Epub 2023 May 8. Lawn JE, Ohuma EO, Bradley E, Idueta LS, Hazel E, Okwaraji YB, Erchick DJ, Yargawa J, Katz J, Lee ACC, Diaz M, Salasibew M, Requejo J, Hayashi C, Moller AB, Borghi E, Black RE, Blencowe H; Lancet Small Vulnerable Newborn Steering Committee; WHO/UNICEF Preterm Birth Estimates Group; National Vulnerable Newborn Measurement Group; Subnational Vulnerable Newborn Measurement Group Effect of Aspirin Coadministration on the Safety of Celecoxib, Naproxen, or Ibuprofen. J Am Coll Cardiol. 2018 Apr 24;71(16):1741-1751. doi: 10.1016/j.jacc.2018.02.036. Reed GW, Abdallah MS, Shao M, Wolski K, Wisniewski L, Yeomans N, Lüscher TF, Borer JS, Graham DY, Husni ME, Solomon DH, Libby P, Menon V, Lincoff AM, Nissen SE Ingesta dietética y adherencia a la dieta mediterránea en un grupo de estudiantes universitarios en función de la práctica deportiva. Nutr Hosp. 2016 Sep 20;33(5):583. doi: 10.20960/nh.583. Redondo Del Río MP, De Mateo Silleras B, Carreño Enciso L, Marugán de Miguelsanz JM, Fernández McPhee M, Camina Martín MA Maltol induces diabetic fragility fractures by disrupting the balance of bone remodeling. Cell Metab. 2026 Mar 27:S1550-4131(26)00095-1. doi: 10.1016/j.cmet.2026.03.001. Wang J, Wang Z, Feng J, Zhang Y, Yao L, Zhang Y, Zhang R, Cai J, Yu H, Deng S, Chen X, Liang R, Huang C, Li J, Li X, Li Q, Shi X Eusociality in history. Hum Nat. 2014 Mar;25(1):80-99. doi: 10.1007/s12110-013-9186-8. Betzig L Blood plasma proteome-wide association study implicates novel proteins in the pathogenesis of multiple cardiovascular diseases. Cardiovasc Diabetol. 2025 Aug 1;24(1):312. doi: 10.1186/s12933-025-02847-w. Wang JH, Dong SS, Huang W, Wang HA, Liu SS, Ma X, Zhu RJ, Shi W, Wu H, Yu K, Zhang TP, Wang CR, Guo Y, Xue H, Yang TL Coordinated action of a gut-liver pathway drives alcohol detoxification and consumption. Nat Metab. 2024 Jul;6(7):1380-1396. doi: 10.1038/s42255-024-01063-2. Epub 2024 Jun 20. Fu Y, Mackowiak B, Lin YH, Maccioni L, Lehner T, Pan H, Guan Y, Godlewski G, Lu H, Chen C, Wei S, Feng D, Paloczi J, Zhou H, Pacher P, Zhang L, Kunos G, Gao B Covalently Engineered Nanobody Chimeras for Targeted Membrane Protein Degradation. J Am Chem Soc. 2021 Oct 13;143(40):16377-16382. doi: 10.1021/jacs.1c08521. Epub 2021 Oct 1. Zhang H, Han Y, Yang Y, Lin F, Li K, Kong L, Liu H, Dang Y, Lin J, Chen PR |
||